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ABSTRACT
BEHAVIORAL, PHYSIOLOGICAL, AND MOLECULAR CHARACTERIZATION OF
LONG-TERM ADMINISTRATION OF A NOVEL ESTROGEN RECEPTOR BETA
AGONIST IN A MOUSE MODEL OF MENOPAUSE
by
Aaron Fleischer
The University of Wisconsin-Milwaukee, 2021
Under the Supervision of Dr. Karyn Frick
The menopausal loss of circulating hormones, including estrogens, is associated with
negative symptoms, such as hot flashes, anxiety and depression, cognitive decline, and
weight gain. Although estrogenic hormone therapies (HT) prevent many of the negative
symptoms related to the menopausal transition, these same therapies are associated
with increased health risks, such as the development of breast and ovarian cancers,
which is mediated by the activation of the a (ERa), but not b (ERb), estrogen receptor
isoform. Furthermore, ERb agonism has previously been shown to reduce preclinical
indices of hot flashes, memory decline, anxiety, and depression. As most ERb agonists
are only modestly selective for ERb over ERa, more selective ERb agonists are needed
as potential therapeutics for menopausal women. As part of a multi-university
collaboration, we have helped to develop a novel ERb agonist, EGX358, which has 750fold selectivity for ERb over ERa without any off-target receptor activation or inhibition.
Although we have shown that acute treatment with EGX358 enhances memory
consolidation in young ovariectomized (OVX) mice, we have yet to investigate this novel
agonist’s effects when administered long-term. In the current study, we orally treated
young, OVX female mice via gavage with vehicle, the highly potent estrogen 17b-
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estradiol (E2), the commercially available ERb agonist diarylpropionitrile (DPN), or
EGX358 for 64 days. Mice were weighed weekly and tested for vasomotor outcomes
following peripheral injection with a neurokinin B agonist, anxiety- like behaviors in the
open field and elevated plus maze, depression-like behaviors in the tail suspension and
forced swim tests, and memory in the object placement and recognition tasks, and
measured for baseline tail skin temperature at the end of the study. On the final day of
treatment, mice were euthanized 30 minutes following gavage, and tissues from the
dorsal hippocampus, medial prefrontal cortex, amygdala, and hypothalamus – regions
highly implicated in memory, affect, and vasomotor symptoms – were collected rapidly
for subsequent Western blot analyses. Mice treated with E2, DPN, and EGX358 all had
reduced drug-induced increases in tail skin temperature relative to vehicle-treated mice
and showed greater performance in both memory tasks than chance levels. E2 also
reduced anxiety-like behaviors and baseline tail skin temperature relative to vehicletreated mice. No other treatment effects were noted for anxiety- or depression-like
behaviors, or on body weight over time. Surprisingly, there were also no treatment
effects on expression or phosphorylation of proteins related to cellular activation,
cellular signaling, pre- or postsynaptic strengthening, or sensitivity to glutamatergic
signaling in any region examined. Additionally, there were no differences in ERb levels
in the hippocampus or prefrontal cortex, suggesting that loss of sensitivity to treatment
was not the reason for a lack of molecular results. Altogether, our results indicate good
potential for further development of EGX358 as a new ERb-selective HT option for
menopause-related symptoms, although its molecular mechanisms remain unknown.
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Introduction
The menopausal transition, primarily characterized by the loss of circulating
hormones such as estrogens, is often associated with many negative symptoms. Among
these, hot flashes, anxiety, depression, cognitive decline, and weight gain are cited
regularly as potent disruptors to women’s quality of life (Bosworth et al., 2001;
Bromberger et al., 2013; Epperson et al., 2013; Lovejoy, 1998; Mitchell & Woods, 2001;
Woods & Mitchell, 2005). Importantly, these symptoms compound upon one another,
further exacerbating the detrimental effects of this transitional life event (Gold et al., 2000;
Greendale et al., 2010; Maki et al., 2008; Maki, 2013). Therefore, it is imperative that
treatments be developed to prevent and reduce the negative symptoms associated with
the menopausal transition. Estrogenic hormone therapies (HTs) are available and have
been used successfully in the past to reduce menopausal symptoms, although these
treatments are also associated with increases in risks to women’s health, such as ovarian
and breast cancer development (MacLennan et al., 2004; Maki, 2013; Péqueux et al.,
2012; Schmidt et al., 2000). Importantly, many of the detrimental effects of HTs appear
to be mediated by the activation of the a (ERa), but not b (ERβ), estrogen receptor isoform
(MacLennan et al., 2004; Péqueux et al., 2012; Schmidt et al., 2000). Therefore, future
HTs should specifically target ERb in order to provide the beneficial effects of estrogenic
treatment while avoiding the deleterious effects of ERa activation. We have recently
worked with collaborators to develop and begin testing a promising novel, highly selective
ERb agonist, EGX358, although the effects of long-term administration of this compound
are currently unknown. The objective of this thesis was to test the efficacy of long-term
EGX358 administration in an ovariectomized (OVX) mouse model of menopause to
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reduce preclinical indices of menopause-related symptoms and influence protein
expression in ERb-laden brain regions.
Review of the Literature: Estrogen-Based Hormone Replacement Therapies
Premarin, a conjugated equine estrogen, has been among the primary HT options
for treating menopausal symptoms decades due to its efficacy in reducing symptom
incidence and severity (Grady et al., 1992; Grodstein et al., 1997; Kimura, 1995; Maki,
2013). However, the initial findings from the Women’s Health Initiative, the largest study
examining the effects of HT in post-menopausal women showed that long-term treatment
with equine estrogens and progestin increased the risks of developing coronary heart
disease, stroke, pulmonary embolism, and invasive breast cancer (Rossouw et al., 2002).
Subsequent work suggests that these side effects are due to activation of ERa, rather
than ERb. For example, single-nucleotide polymorphisms on the ERa gene which
facilitate greater binding affinity for the potent estrogen, 17b-estradiol (E2), to ERa, are
associated with increased risks for cardiovascular disease, coronary artery disease, and
stroke (Alevizaki et al., 2007; Shearman et al., 2003, 2005). Additionally, others have
demonstrated that chronic E2 treatment in OVX female wild type and ERb knockout mice,
but not ERa knockout mice, promotes tumor cell growth (Péqueux et al., 2012).
Furthermore, Premarin is comprised of more than 50% estrone, which has a higher affinity
for binding ERa compared to ERb (Englund & Johansson, 1978; Perkins et al., 2017).
These lines of evidence suggest that the deleterious side effects associated with HT may
be mediated by ERa activity.
Phytoestrogens: An ERb-Selective Treatment Method
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Phytoestrogens are a class of compounds found in many different plant species,
and these compounds interestingly demonstrate selective affinity for ERb as compared
to ERa (Cheng et al., 2007; Nikov et al., 2000). Among these, isoflavones are the most
commonly found and used in both preclinical and clinical studies, demonstrating between
8- and 68-fold selectivity for ERb (Cheng et al., 2007; Nikov et al., 2000). When tested
clinically and preclinically, phytoestrogens are indeed capable of reducing menopausal
symptoms and even demonstrate efficacy in reducing cancer cell proliferation. For
example, 3 months of isoflavone treatment reduced hot flash occurrences by 50% in
postmenopausal women, and 12 weeks of treatment with MF101, an ERb-selective
herbal extract, also reduced hot flash incidences (Cheng et al., 2007; Grady et al., 2009).
Additionally, ERb-selective phytoestrogens have been shown to reduce ovarian cancer
cell proliferation rates in cell cultures, as well as reduce the growth of tumors in mouse
models (Sareddy et al., 2012; Schüler-Toprak et al., 2017). Although these results are
promising in terms of developing ERb-selective treatments, it is difficult to attribute these
effects solely to phytoestrogens, given that these compounds are found ubiquitously in
commonly consumed foods. Additionally, although phytoestrogens are somewhat
selective for ERb over ERa, greater selectivity will provide more assurance that long-term
treatment would not inadvertently target ERa as well. Thus, treatment options with greater
selectivity for ERb are needed.
EGX358, a Novel, Highly Selective ERb Agonist
Synthetic ERb agonists are readily available for commercial purchase, and these
have shown preclinical efficacy for reduction of cancer cell proliferation in cell culture,
improvement of memory and anxiety- and depression-like outcomes in rodents (Boulware
3

et al., 2013; Hanson et al., 2018; Lund et al., 2005; Pereira et al., 2014; Rocha et al.,
2005; Walf et al., 2004). It should be noted, however, that these compounds also have
relatively low selectivity for ERb, as the most commonly used agonist, diarylpropionitrile
(DPN, Figure 1), is only about 70-fold more selective for ERb over ERa (Meyers et al.,
2001). Therefore, there is a need for ERb agonists with greater selectivity.
As part of a multi-institutional collaboration, our laboratory has spent the past six
years developing a novel, highly selective ERb agonist, EGX358 (Figure 1). EGX358
closely resembles the structure of the native E2,
and has been classified as an “A-C” estrogenic
compound, as the “B” cyclohexane and “D”
cyclopentane groups have been reduced to
simplify the E2 structure into a 4-hydroxymethylcyclohexane ring tethered to a phenolic ring
(Hanson et al., 2018). EGX358 exhibits 750-fold
selectivity for ERb over ERa, and does not
produce

off-target

effects

on

androgen,

glucocorticoid, mineralocorticoid, peroxisome
proliferation-activated, progesterone, thyroid
hormone, or vitamin D receptors, thereby
making it the most selective synthetic ERb
Figure 1. Structure and ERβ Selectivity of
EGX358. Structural comparisons of 17βestradiol, DPN, and EGX358.

agonist to date (Hanson et al., 2018). Acute

treatment with EGX358 delivered peripherally via oral gavage or intraperitoneal injection,
or bilaterally infused directly into the dorsal hippocampus (DH), immediately post-training
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enhances both object placement (OP) and object recognition (OR) memory consolidation
in OVX mice (Hanson et al., 2018). However, the effects of long-term treatment of
EGX358 are currently unknown. As we continue to develop this compound as a potential
therapeutic for menopause-related symptoms, it is imperative to determine the long-term
behavioral, physiological, and cellular and molecular effects of this compound in a
preclinical model.
Preclinical Models of Menopausal Symptoms and their Treatment with ERb Agonists
The most common method of modeling menopause preclinically is through
bilateral ovariectomy of young female rodents. This surgical method allows for the
removal of the primary sources of circulating estrogens and progestins. However, as
useful as OVX is for eliminating circulating sex hormones, it should be noted that this
immediate loss of hormones does not recapitulate the gradual processes of aging and
ovarian senescence in menopause, as the majority of women experiencing menopause
retain their ovaries (Koebele & Bimonte-Nelson, 2016). Nevertheless, OVX in young mice
has been widely adopted in the field as a method to mimic the effects of ovarian hormone
loss and resulting disruption to the hypothalamic-pituitary-gonadal axis. Bilateral OVX is
capable of increasing anxiety- and depression-like behaviors, while also impairing spatial
and object recognition memories relative to sham control surgery in female rodents (Walf
& Frye, 2006; Wallace et al., 2006). Although OVX also increases tail skin temperature,
a measure of vasodilation used as a proxy of hot flashes, this is a very gradual occurrence
that does not model well the rapid experiences of hot flashes, which are driven largely by
disrupted neurokinin B signaling in the median preoptic area of the hypothalamus
resulting from the loss of estrogenic negative feedback in the arcuate nucleus (Padilla et
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al., 2018; Rance et al., 2013; Tan et al., 2016). More recently, a synthetic agonist of
tachykinin 3 receptors, which are primarily responsible for the actions of neurokinin B,
has been developed. This agonist, senktide, is a potent tachykinin 3 receptor agonist
which elicits a pronounced, transient increase in tail skin temperature in intact male and
female, as well as OVX female mice (Krajewski-Hall et al., 2018; Krull et al., 2017). Thus,
ovariectomy and administration of senktide are effective preclinical methods to produce
several symptoms of menopause.
Importantly, the effects of OVX and senktide can be reduced by estrogenic
compounds. For example, we and others have demonstrated that acute and long-term
administrations of E2, DPN, or phytoestrogens enhance memory function in OVX rodents,
particularly in spatial and object recognition tasks (Boulware et al., 2013; Hanson et al.,
2018; Jacome et al., 2010; Pereira et al., 2014; L. Zhao et al., 2011). Furthermore, the
ability of E2 to reduce anxiety- and depression-like behaviors in OVX rodents appears to
be mediated largely by ERb activation, as ERb, but not ERa, agonists decrease these
behaviors, and genetic knockout of ERb, but not ERa, blocks E2’s anxiolytic and antidepressive effects (Eid et al., 2020; Lund et al., 2005; Oyola et al., 2012; Walf & Frye,
2006). Although no previous studies have specifically examined the role of ERb signaling
in senktide-mediated vasodilation, E2 delivered chronically does reduce senktide’s effects
on vasodilation (Krajewski-Hall et al., 2018). A role for ERb is suggested by data from
ERa knockout mice, in which E2 reduced gradual increases in baseline tail skin
temperature following OVX, and by another study in wildtype mice in which long-term
treatment with an ERb-selective phytoestrogen diet prevented OVX-associated increases
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in baseline tail skin temperature (Opas et al., 2006; L. Zhao et al., 2011). These findings
suggest a possible role for ERb signaling in preventing hot flash-like symptoms.
Together, existing evidence suggests that OVX in young mice can reproduce key
symptoms of menopause and ERb activation is a promising method for alleviating these
symptoms. Thus, there is a strong basis to suggest that long-term treatment with ERb
agonists, including EGX358, could present a safe and effective method for treating
menopausal symptoms.
Effects of ERb Activation in the Brain
The three main estrogen receptors, ERa, ERb, and G-protein coupled estrogen
receptor, are widely distributed throughout the brain and influence neural activity when
an estrogenic ligand is present (Alexander et al., 2017; Almey et al., 2014; Dacks et al.,
2011; Mitra et al., 2003; Oberlander & Woolley, 2017; Shughrue et al., 1997). In particular,
ERb is found throughout the hippocampus, medial prefrontal cortex (mPFC), amygdala,
and hypothalamus, regions highly associated with learning and memory, affective
symptoms, and thermoregulation (Almey et al., 2014; Mitra et al., 2003; Shughrue et al.,
1997). Thus, these regions are of particular interest in determining the molecular
mechanisms by which ERb agonism might affect menopausal symptoms.
Within the DH, which is implicated in both memory outcomes and affective
symptoms, the Frick lab has demonstrated repeatedly that acute bilateral infusion of E2
enhances spatial and object memory consolidation in OVX mice through upregulation of
extracellular signal-regulated kinase (ERK) phosphorylation, brain-derived neurotrophic
factor (BDNF), and cofilin phosphorylation, among others, which all converge to facilitate
synaptic plasticity, as indicated by increased CA1 dendritic spine density in this region
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(Buzsáki & Moser, 2013; Fernandez et al., 2008; Gross et al., 2021; J. Kim et al., 2019;
Tuscher, Luine, et al., 2016; Zhu et al., 2019). We and others have also shown that acute,
bilateral infusion or up to 7 days of peripheral treatment with ERb agonists also upregulate
plasticity-mediated protein expression and activation in the DH of young and old OVX
female mice, respectively; namely phosphorylation of ERK and cofilin, upregulation of the
F-actin:G-actin ratio, and increased CA1 spine densities are all results of ERb agonism
in the DH (Boulware et al., 2013; Y. Zhao et al., 2017). Although few studies have
examined the molecular effects of long-term ERb activation, at least one study has
demonstrated that long-term treatment with ERb-selective phytoestrogen-rich diets
increases BDNF and PSD95 expression in the hippocampus (L. Zhao et al., 2011).
Additionally, DPN administered for 29 days resulted in greater GluA2 and GluA3 mRNA
in the hippocampi of OVX rats, suggesting a greater sensitivity to glutamatergic signaling
in this region due to ERb activity (Sárvári et al., 2016). Therefore, the above are all
potential targets by which EGX358 might influence memory outcomes.
As with the hippocampus, the mPFC serves a dual role in memory and emotional
processing, and this region appears to be highly sensitive to the effects of estrogenic
signaling with a potential role of ERb activation. We and others have demonstrated this
by acutely treating OVX rodents via either peripheral injection or direct bilateral infusion
with E2, which increases expression of the immediate early gene c-Fos, a marker of
cellular activity, and dendritic spine densities within 2 hours (Tuscher et al., 2019; Zeidan
et al., 2011). Additionally, although less is known about the specific role of ERb activation
in the mPFC, ERb are poised to mediate these effects given their localization to mPFC
axon terminals, dendritic spines, and glia in rats (Almey et al., 2014). Additionally,
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peripheral injection of DPN is sufficient to increase dopamine, serotonin, and their
metabolites HVA and 5HIAA, respectively, in the mPFC, and 8 weeks of phytoestrogenrich diets increase BDNF mRNA expression therein, suggesting involvement of ERbspecific mechanisms in this region (Jacome et al., 2010; Pan et al., 1999). These ERb
localizations and plasticity-related changes indicate that long-term ERb agonism may
enhance synaptic connectivity in the mPFC in similar ways as in the DH, although much
more work is needed to determine the veracity of this speculation.
Much less is known about the molecular mechanisms through which ERb activity
in the amygdala and hypothalamus might influence affective and vasodilatory outcomes,
respectively. In the amygdala of OVX rats, E2 infusion into the central or medial nuclei
reduces anxiety- and depression-like behaviors, an effect thought to be mediated by ERb
activity (Frye & Walf, 2004; Le Moëne et al., 2019). These behavioral outcomes may
result from reduced cellular activity in the amygdala, as E2 treatment in gonadally intact
rats in the low-estrogen metestrus phase decreases c-Fos expression (Zeidan et al.,
2011). Although this finding suggests that E2 reduces synaptic plasticity in the amygdala,
much more needs to be done to investigate a role for ERb-driven molecular candidates
in the reduction of affective behaviors. Similarly, it is known that vasomotor symptoms are
associated with increases in c-Fos expression in the median preoptic area and arcuate
nucleus of the hypothalamus are associated with increased hot flash-like symptoms and
that long-term treatment with E2 in OVX rodents both reduces vasomotor symptoms and
prevents elevations in c-Fos in these regions (Dacks et al., 2011; Krull et al., 2017).
However, to date, no studies have investigated the roles of ERb activity in these brain
region with respect to hot flash-like indices. Therefore, further investigation is needed to
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determine whether and how ERb agonism might affect this region, especially with regard
to vasomotor outcomes.
Goals of this Thesis
The primary objective of this thesis was to determine the extent to which long-term
oral treatment with EGX358 in OVX mice enhances memory, alleviates senktide-induced
vasodilation, reduces anxiety- and depressive-like behaviors, influences body weight, and
regulates levels of cell-signaling, synaptic, and growth factor proteins in the DH, mPFC,
amygdala, and hypothalamus. Mice were gavaged daily for 64 days with vehicle, E2,
DPN, or EGX358, during which time they were tested for senktide-mediated tail skin
temperature responses, open field and elevated plus maze indices of anxiety-like
behavior, tail suspension and forced swim test indices of depression-like behavior, spatial
and object memory as tested in the object placement and object recognition paradigms,
and long-term changes in baseline tail skin temperature. On the final day of treatment,
mice were euthanized, and tissues from the DH, mPFC, amygdala, and hypothalamus
were collected and subsequently analyzed via Western blot for markers of cellular activity
(c-Fos), phosphorylation of rapid kinases (p42 ERK and CaMKIIα), neurotrophic factors
(BDNF), presynaptic markers of vesicular release of neurotransmitters (SNAP25,
synaptophysin), postsynaptic markers of plasticity (PSD95, GluA ratio), and postsynaptic
markers of actin remodeling (F-actin, phospho-cofilin), as well as ERb. Our results
indicate that long-term oral EGX358 treatment can reduce senktide-induced vasodilation
and enhance both object recognition and object placement memory outcomes to similar
extents as E2 and DPN, but that only E2 treatment reduces anxiety-like behaviors and
baseline tail skin temperature compared to vehicle treatment. DPN and EGX358 did not
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affect anxiety- or depression-like behaviors or baseline tail skin temperature compared to
vehicle, and there were no treatment effects on body weight following OVX. Surprisingly,
none of the estrogen treatments altered protein levels in any brain regions examined.
Thus, although the mechanisms underlying its effects remain elusive, EGX358’s
beneficial effects on several preclinical indices of menopausal symptoms, without
concomitant negative effects on affective behaviors or body weight, make it a promising
lead compound for alleviating memory dysfunction and hot flashes in menopausal
women.

Methods and Materials
Subjects
Subjects were eight-week-old female C57BL/6 mice (n=40), obtained from Taconic
Biosciences (Germantown, New York). Mice were housed five per cage until 24 h prior to
surgery. Following surgery, mice were singly housed for the duration of the experiment.
Mice were maintained on a 12-hour light-dark cycle (lights on at 07:00) and were given
food and water access ad libitum. Diet was standard rodent chow (Teklad Rodent Diet
8604, Envigo, Madison, WI), which contained isoflavone equivalents of daidzein and
genistein aglycone ranging from 350 to 650 mg/kg. Handling to acclimate mice to the
experimenters began one week after surgery. All treatments and behavioral testing
occurred during light hours. All procedures followed the National Institutes of Health
Guide for the Care and Use of Laboratory Animals and were approved by the University
of Wisconsin-Milwaukee Institutional Animal Care and Use Committee.
General Experimental Design
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The experimental timeline for the study is illustrated in Figure 2, with additional
visual representations of the procedures used depicted in Figures 3 and 4. Three days
after arrival in the lab, mice were ovariectomized (Figure 2). Mice were weighed

Figure 2. Experimental timeline. Young female C57BL/6 mice were bilaterally ovariectomized at
approximately 8 weeks of age. Mice recovered for 7-8 days, after which wound clips were removed.
The next day, mice began daily oral gavage treatment (10% DMSO, E2, DPN, or EGX358). Daily oral
gavage continued for the duration of the experiment, 64 days in total. During the first 2 weeks of
treatment, mice were also subcutaneously injected with 0.9% saline every other day. Following the
first 2 weeks of treatment, mice began behavioral testing, which was conducted in the following order:
TSkin with subcutaneous injection of 0.9% saline (vehicle), TSkin with subcutaneous injection of senktide,
open field, elevated plus maze, tail suspension test, forced swim test. After completing the forced
swim test, mice were gavaged without behavioral testing for 8 days, after which they began object
placement and, subsequently, object recognition training and testing. The day after completion of
object testing, mice were thermally imaged for TSkin 1 hour following gavage. On the final day of the
experiment, mice were gavaged and euthanized 30 minutes later, and brain tissue was rapidly
dissected and stored at -80°C. Mice were gavaged 1 hour prior to each behavioral test. DMSO,
dimethyl sulfoxide; E2, 17b-estradiol; DPN, diarylpropionitrile; TSkin, tail skin temperature.

immediately prior to surgery and once weekly throughout the remainder of the study to
appropriately dose treatments and to test for effects of treatment on weight gain.
Following recovery from OVX surgery, mice were gavaged daily with their respective
treatments for two weeks in their colony room without being behaviorally tested. During
this two-week period, mice were also given subcutaneous (SC) injections of 0.9% saline
every other day to acclimate them to injection stress prior to vasodilation measurements.
Daily gavage continued throughout the duration of the study, and mice were gavaged in
their colony room 1 h prior to testing on days of behavioral and physiological
measurements, unless otherwise noted. This timepoint was chosen because of the
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number and variety of behavioral tasks in the current study. Due to the wide variety of
times at which estrogenic compounds elicit behavioral (Bekku & Yoshimura, 2005;
Bernardi et al., 1989; Estrada-Camarena et al., 2003; Gresack & Frick, 2006a; Harburger
et al., 2007; Li et al., 2014; Lund et al., 2005; Oyola et al., 2012) and neural effects (Eid
et al., 2020; Galea, 2008; Inagaki et al., 2010, 2012; Jacome et al., 2010; Phan et al.,
2012) when administered peripherally to ovariectomized rats and mice, and given that the
time frame in which systemically-administered EGX358 activates ERb in the brain is
currently unknown, one hour was chosen to allow sufficient time for the compound to
cross the blood-brain barrier and bind ERb in target brain regions.
Mice were first tested for vasodilation responses to vehicle, and then senktide,
administration. Next, anxiety-like behaviors were measured in the open field (OF) and
elevated plus maze (EPM). Then, depression-like behaviors were measured in the tail
suspension test (TST) and forced swim test (FST). Following completion of FST, mice did
not undergo behavioral testing for one week to mitigate potential effects of accumulated
stress on memory tests. Then, mice were trained and tested in OP and OR to assess
memory. Finally, mice were thermally imaged one day following memory testing to
determine long-term effects of treatment on baseline thermal regulation. Following
completion of all measurements, mice were gavaged and euthanized 30 min later, and
tissue from ERb-laden brain regions implicated in menopause-related symptoms was
rapidly dissected and collected on wet ice and frozen at -80°C for follow-up biochemical
studies at a later date.
All behavioral tasks were conducted in lighting <100 lux and ambient room
temperature of 23 ± 2°C. To reduce the chances of mice associating a given behavioral
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testing room with stressful situations, tests were conducted in three separate rooms:
vehicle and senktide vasodilation measures, TST, and FST were conducted in one; OF,
OP, and OR were conducted in a second; and EPM was conducted in the third. The final
gavage and euthanasia were conducted in a fourth room. Thermal images and all gavage
treatments prior to euthanasia were conducted in the colony room. Additionally, during all
behavioral test sessions, a researcher blind to treatment initiated recordings in rooms
adjacent to those in which the behavior was being conducted, and researchers remained
outside of the testing rooms during testing. All behavioral and physiological
measurements were quantified and recorded by researchers blind to treatment following
completion of a given task, unless otherwise noted.
Ovariectomy Surgery
Mice were singly housed 24 h prior to surgery. On the day of surgery, mice were
bilaterally ovariectomized using a procedure that our laboratory has repeatedly employed
to eliminate circulating estrogens (Frick & Berger-Sweeney, 2001; Gresack & Frick,
2006b; Hanson et al., 2018; Koss et al., 2018; Tuscher, Luine, et al., 2016), as previously
verified by vaginal lavage (Frick & Berger-Sweeney, 2001). Briefly, on the day of surgery,
mice were anesthetized with isoflurane (5% for induction, 2% for maintenance).
Immediately after anesthesia induction, mice were given a SC injection of Rimadyl (1:100,
10 mL/kg) for analgesia. Mice were then shaved bilaterally on their flanks and incised,
after which their ovaries, oviducts, and tips of the uterine horns were ligated with
monofilament and then removed, as confirmed by visual observation. Muscle wall
incisions were sutured with chromic gut, and skin incisions were closed with wound clips.
Mice recovered for seven days, the first two days of which they were given SC Rimadyl
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injections for post-operative analgesia. Following this recovery period, wound clips were
removed, and mice were replaced in their colony room.
Drugs and Administration
Following recovery from surgery and wound clip removal, mice were handled
briefly (30 s/day) for three
days

to

habituate

experimenter

to

handling

(Figure 2). On the fourth
day, mice began daily
gavage

treatment

(n=10/group) in the colony
room
gastric

using

bulb-tipped

gavage

needles

(24 GA, 25 mm) (Hanson
et al., 2018). Mice
were
daily
weeks

gavaged
for
prior

two
to

behavioral testing
and

throughout

the rest of the
study. On days of
physiological

Figure 3. Visual representations of behavioral tasks. Young,
ovariectomized mice were gavaged with 10% DMSO, E2, DPN, or EGX358 1
hour prior to each behavioral or physiological measurement. Diagrams
represent each behavioral apparatus. Mice were thermally imaged for tail skin
temperature following subcutaneous injection of 0.9% saline and,
subsequently, senktide for 30 minutes. Next, mice were measured for anxietylike and locomotor behaviors in the open field, namely time spent in and entries
into each zone, as well as distance traveled during the 10-minute test. Mice
were then measured for anxiety-like behaviors in the elevated plus maze for 10
minutes, quantified as entries into and time spent in each set of arms and the
center space. Mice were measured for time spent immobile and latency to first
bout of immobility as proxies of depression-like behaviors in the tail suspension
test for 6 minutes and, subsequently, the forced swim test for 4 minutes. Mice
were tested for memory consolidation in the object placement and object
recognition tasks by measuring time spent with the moved or novel objects,
respectively, during the testing phase of each task. Finally, mice were thermally
imaged for tail skin temperature 1 hour after gavage on the final day of the
experiment. DMSO, dimethyl sulfoxide; E2, 17b-estradiol; DPN,
diarylpropionitrile. Created with BioRender.com.
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measurements and behavioral training and testing, mice were gavaged 1 h prior to
measurement (Figure 3). Mice received β-cyclodextrin-encapsulated E2 (Sigma-Aldrich,
0.2 mg/kg), DPN (Tocris Biosciences, 0.05 mg/kg), or EGX358 (0.5 mg/kg), at doses
previously shown to enhance hippocampus-dependent memory consolidation when
administered systemically (Gresack & Frick, 2006; Hanson et al., 2018). Given the
hydrophobicity of EGX358 (Hanson et al., 2018), we have previously dissolved this
compound in 10% DMSO when acutely treating mice peripherally via gavage or
intraperitoneal injection (Hanson et al., 2018). Thus, each treatment in the current study
was dissolved in 10% DMSO in 0.9% saline, and all treatments were administered at 10
mL/kg, as described previously (Hanson et al., 2018). Vehicle-treated mice received 10%
DMSO in 0.9% saline daily. To acclimate the mice to injection stress prior to vasodilation
measurements, mice were given a SC injection of 0.9% saline (5 mL/kg) every other day
during the two weeks prior to behavioral testing. During vasodilation experiments, mice
were given a single SC injection of either vehicle (0.9% saline, 5 mL/kg) or senktide
(Tocris Biosciences, 0.5 mg/kg, 5 mL/kg) dissolved in 0.9% saline.
Tail Vasodilation Response
To measure the effects of long-term treatment on vasomotor symptoms, tail skin
temperature (TSkin), a proxy for vasodilation (Figure 3), was measured three times, as
described previously (Krajewski-Hall et al., 2018; Krull et al., 2017; Padilla et al., 2018).
On days of vehicle or senktide challenge, each mouse was transported to a testing room
immediately following gavage and given 1 h to acclimate to the new environment prior to
testing. In its home cage, each mouse was placed in a secondary container (10 in x 18 in
x10 in) beneath a thermal camera (E8, FLIR, Wilsonville, OR, USA). After acclimation,
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the cage top was removed and a researcher in an adjacent room initiated continual
thermal imaging (FLIR Tools+). Baseline TSkin was recorded for 10 min to ensure there
were no effects of stress or activity due to removal of the cage top. Then, a researcher
removed the mouse from its home cage and injected the mouse SC with either vehicle or
senktide. The mouse was then returned to its home cage, and TSkin was recorded for an
additional 20 min. After testing, the cage top was placed back onto the cage, and the
mouse was removed from the testing room. On the final experimental day of the study,
mice were imaged one time in their colony room 1 h following gavage to determine the
effects of long-term treatment with E2, DPN, or EGX358 treatment on TSkin following
ovariectomy..
Following completion of behavioral testing, TSkin from these experiments was
quantified using FLIR Tools+ software. TSkin was measured by averaging the temperature
of the tail in a 1-cm line beginning 2 cm from the tail base, as described by others (Krull
et al., 2017). During the vehicle and senktide challenges, the researcher quantified TSkin
immediately following the removal of the cage top, as well as at 5 and 7.5 min following
cage top removal to ensure that temperature changes were not due simply to stress or
increased activity associated with the removal of the cage top. Beginning immediately
following SC injection, TSkin was measured every minute for 20 min to assess the acute
effects of vehicle or senktide administration. When a tail was obscured at the exact minute
of the recording, TSkin was measured at the next full second when the tail was exposed.
Mice were analyzed for change in TSkin (DTSkin) due to injection, which was calculated via
the following equation: (TSkin, Raw – TSkin, Baseline), where TSkin, Raw was the TSkin quantification
at a given time point, and TSkin, Baseline was the TSkin at 7.5 min following cage top removal,
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such that changes in temperature were normalized to the temperature measured most
immediately prior to injection (Krajewski-Hall et al., 2018; Krull et al., 2017). Images
captured on the last day of the experiment were quantified for TSkin. Previously, KrajewskiHall et al. (2018) utilized a threshold of 30°C, above which mice were removed from
analyses of senktide-induced TSkin measurements. Based upon our own preliminary
studies, we determined that TSkin exceeding 27°C prior to peripheral injection is indicative
of measurement-induced stress and/or increased activity (data not shown), thereby
obfuscating effects of senktide on tail vasodilation as measured by thermal imaging.
Therefore, based on this previous literature and our own preliminary studies, mice were
removed from vehicle (n=1, DPN) or senktide (n=1, DPN) analyses if their TSkin, Baseline
was above 27°C (Krajewski-Hall et al., 2018). Additionally, mice were removed from
senktide challenge analyses if they did not exhibit tail rattles or cold-seeking behaviors,
such as pushing bedding aside to expose the cool bottom of the cage (n=1, Vehicle), both
of which are stereotypical responses to senktide treatment (Krajewski-Hall et al., 2018;
Krull et al., 2017).
Open Field Test
The open field (OF) test assessed locomotor and anxiety-like behaviors (Li et al.,
2014; Lund et al., 2005; Oyola et al., 2012; Rocha et al., 2005). The OF arena consisted
of an empty white testing box (60 cm x 60 cm x 47 cm) that was divided into a 5 x 5 grid
of squares (12 cm x 12 cm). This grid included an outer zone (16 squares total), a middle
zone (8 squares total), and a center zone (1 square total) (Figure 3). Mice were
transported to a holding room immediately following gavage and remained in the room
for 1 h prior to testing to acclimate to a new environment. Mice were placed in the lower
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center of the OF arena, facing the bottom wall, and given 10 min to explore. ANY-maze
software (Stoelting) automatically tracked the center of each mouse’s body and quantified
distance travelled in, time spent in, and number of entries into each zone. The number of
fecal boli in each zone, as well as the number of bouts and time spent both
grooming/barbering and rearing, were manually quantified. After testing, each mouse was
immediately returned to its home cage and removed from the testing room, and the OF
arena was cleaned with 70% ethanol between each test.
Elevated Plus Maze
The elevated plus maze (EPM) was also used to measure anxiety-like behavior
(Frick et al., 2000; Lund et al., 2005; Oyola et al., 2012). The open arms of the EPM
apparatus (30 cm x 5 cm) consisted of an opaque white Plexiglas floor with a clear lip (0.5
cm) attached to the sides of each arm to prevent mice from falling off the apparatus
(Figure 3). The closed arms (30 cm x 5 cm x 15 cm) consisted of opaque black Plexiglas
walls and a gray floor. Mice were transported to a holding room, gavaged, and given 1 h
to acclimate to the new environment before moving to a testing room. Then, each mouse
was placed in the EPM. Mice were placed in the center of the maze, facing the upper
open arm, and behavior was recorded via ANY-maze for 10 min. Following completion of
EPM testing, the number of fecal boli, number of entries into, and time spent in each set
of arms and the center zone were quantified. An entry into either set of arms was
determined as a mouse having all four paws within an arm. Otherwise, mice were
considered to be in the center zone. Time spent peeking into open arms was also
quantified, defined as any time the mouse either oriented its head and up to three paws
into an open arm or was looking over the side of the apparatus. Mice were immediately
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placed back into their home cages and removed from the room after testing, and the EPM
was cleaned with soap and water between each test. One mouse (EGX358 group) was
removed from analyses because it fell off of the apparatus during the test.
Tail Suspension Test
The tail suspension test (TST) assessed depression-like behavior (Bernardi et al.,
1989; Can et al., 2011). The TST apparatus was made of opaque white Plexiglas and
consisted of three chambers (10 in x 10 in x 18 in) (Figure 3). A tube was threaded through
a hole in the ceiling of each chamber. C57BL/6 mice are known to climb their tails when
suspended in this manner, making it difficult to quantify mobility and immobility behaviors
(Can et al., 2011). Therefore, a small piece of tubing was placed around the base of each
mouse’s tail to effectively eliminate tail climbing (Can et al., 2011). Each mouse was
suspended in the chamber by its tail, which was taped to the tube 1 cm from the tail tip
and with the mouse’s ventral side facing the camera. The mouse’s behavior was recorded
via ANY-maze for 6 min. Following testing, tubing was removed from each mouse’s tail,
and mice were returned to their home cages and removed from the room. The TST
apparatus was cleaned with soap and water between each test. After testing, the number
of fecal boli, time spent immobile, and latency to first bout of immobility were measured.
Immobility was defined as the mouse remaining motionless or making only those
movements needed to reorient its body, such as small front paw movements, slow
adjustments, or sniffing. Mobility was defined as additional movements, such as full-body
movement, rear paw movement, forceful front paw movement, and the mouse climbing
the fur on its abdomen. To ensure accurate scoring, all tests were scored by a single
researcher blind to treatment, and each test was scored until two independent immobility
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scores were within 3 sec of each other. The average of these two scores was used as the
immobility score for each mouse.
Forced Swim Test
The forced swim test (FST) was used to measure depression-like behavior (Bekku
& Yoshimura, 2005; Can et al., 2011; Estrada-Camarena et al., 2003; Li et al., 2014;
Okada et al., 1997; Rocha et al., 2005). The FST apparatus consisted of a glass cylinder
(14 in x 6 in diameter) filled with water (20 cm depth) to prevent mice from supporting
themselves by touching the cylinder bottom with their paws (Figure 3). Water temperature
was measured between each test and maintained at 23±2 °C, and water was changed
after three mice completed testing. During the FST, each mouse was gently placed into
the water, such that its head was not submerged, and swimming behavior was recorded
for 6 min in ANY-maze. After testing, the mouse was removed from the cylinder, dried
with paper towels, and returned to its home cage. The home cage was then removed
from the testing room and placed on a heating pad for 20 min. The number of fecal boli
was recorded and cleaned from the glass cylinder after each mouse completed the FST.
The first 2 min of each recording were used to acclimate each mouse to the water. The
last 4 min were scored for time spent immobile and latency to first bout of immobility by a
single researcher who was blind to treatment groups. Immobility was defined as the lack
of movement (floating) or only those movements necessary to rectify the mouse’s upright
position. Mobility was defined as additional movements, such as swimming and
attempting to climb the cylinder wall. As with the TST, each test was scored until two
independent immobility scores were within 3 sec of each other. The average of the two
scores was used as the immobility score for each mouse.
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Object Placement and Object Recognition
The object placement (OP) and object recognition (OR) tests (Figure 3) assessed
spatial and object recognition memory, respectively (Boulware et al., 2013; Fernandez et
al., 2008; Fortress, et al., 2013a; Fortress, et al., 2013b; Hanson et al., 2018; Kim et al.,
2016; Tuscher et al., 2016). Briefly, one week after the FST, a Lego Duplo block was
placed in the home cage of each mouse for three days to expose it to an object. Then,
each mouse was habituated to an empty OF box (60 cm x 60 cm x 47 cm) for 5 min/day
for two days. The day after the second habituation, the mouse was placed in the OF box
for 2 min before training with objects. After the 2 min accustomization phase, the mouse
was returned to its home cage while two identical objects were positioned 5 cm from the
upper left and right corners of the OF arena. The mouse was then returned to the OF box
and given 20 min to accumulate 30 s of exploration time with the objects, defined as any
time when the mouse was adjacent to a given object with its nose and/or front paws
directed at and/or touching the object. Exploration was scored live in ANY-maze by a
researcher blind to treatment. Mice underwent OP training and testing prior to OR training
and testing.
OP and OR were tested 24 h and 48 h post-training, respectively. At these time
points, OVX mice treated acutely with E2, DPN, or EGX358, but not vehicle, immediately
post-training spend significantly more time than chance (15 s) with the moved or novel
objects, respectively (Boulware et al., 2013; Hanson et al., 2018; Tuscher et al., 2019;
Kim et al., 2016). During both OP and OR testing, as in training, mice were given 20 min
to accumulate 30 s of exploration between the objects, as scored live in ANY-maze. Mice
that remember the location and identity of the training objects should spend significantly
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more time than chance with moved and novel objects in OP and OR, respectively.
Following testing, each mouse was removed from the OF arena and returned to its home
cage. The OF arena was cleaned with 70% ethanol between mice after each portion of
both OP and OR. Mice were removed from OP (n=1, DPN; n=2, EGX358) or OR (n=1,
Vehicle; n=1, DPN) analyses if they did not reach > 27 s of exploration time with objects
during the training phase and 30 s during the testing phase.
Western Blotting
On day 64 of treatment, mice were euthanized via cervical dislocation and
decapitation 30 min following gavage (Figure 4). Tissues from the DH, mPFC, amygdala,
and hypothalamus were rapidly collected bilaterally from brain block slices on wet ice and
frozen and stored at -80°C. Tissues from each brain region were homogenized and
processed via Western blot as described previously (J. Kim et al., 2016; Koss et al., 2018).
Briefly, samples were resuspended 1:25 w/v in lysis buffer solution and immediately
homogenized via a probe sonicator (Branson Sonifier 250). Next, homogenates were
electrophoresed on Tris-Glycine eXtended (TGX) stain-free precast gels (Bio-Rad) and
transferred rapidly to polyvinylidene fluoride (PVDF) membranes using a TransBlot Turbo
system (Bio-Rad). Membranes were blocked with either 5% or 10% milk suspended in
Tris-buffered saline with Tween 20 (T-TBS) and then incubated with primary antibodies
(anti-phospho-ERK1/2, anti-phospho-cofilin, anti-phospho-CaMKII, anti-GluA1, anti-Factin, anti-PSD95, anti-SNAP25, anti-c-Fos, anti-synaptophysin 1:1000, Cell Signaling
Technology; anti-ERb 1.0 µg/mL, Fisher Scientific; anti-BDNF 1:1000, Abcam) overnight
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at 4°C. The following day, blots were incubated at room temperature for 1 h in rabbit or

Figure 4. Visual representation of tissue collection and Western blot analysis. On day 64 of
treatment, mice received either DMSO (vehicle), E2, DPN, or EGX358 and were euthanized 30 min
later. Tissues were rapidly collected via brain block slices from the mPFC, DH, amygdala, and
hypothalamus and stored at -80°C until Western blot analysis. Tissue homogenates were analyzed
for ERK, cofilin, CaMKII, and BDNF signaling, as well as c-Fos, PSD95, F-actin, synaptophysin,
SNAP25, and ERb levels, and/or the ratio of GluA1:GluA2/3/4, depending upon the brain region
being examined. DMSO, dimethyl sulfoxide; E2, 17b-estradiol; DPN, diarylpropionitrile. mPFC,
medial prefrontal cortex; DH, dorsal hippocampus; Amyg, amygdala; Hypothal, hypothalamus; ERK,
extracellular signal-regulated kinase; CaMKII, calcium/calmodulin-dependent kinase II; BDNF,
brain-derived neurotrophic factor; PSD95, postsynaptic density protein 95; F-actin, filamentous
actin; ERb, estrogen receptor b; GluA, AMPA receptor subunit. Created with BioRender.com.

mouse HRP-conjugated secondary antibody (1:5000, Cell Signaling Technology), and
developed with West Dura chemiluminescent substrate (Pierce). A ChemiDoc MP gel
imager (Bio-Rad) was used to detect signal correlating with protein expression.
Membranes were then stripped twice via 0.2M NaOH washes, re-blocked with 5% or 10%
milk, and subsequently incubated with primary antibodies (anti-total-ERK1/2, anti-totalcofilin,

anti-total-CaMKII,

anti-GluA2/3/4,

anti-b-actin

1:1000,

Cell

Signaling

Technologies) at 4°C and again imaged the next day. Densitometry was performed for
each protein using Image Lab software (Bio-Rad). Phosphorylated protein expressions
were normalized to their total protein expression, GluA1 expression was normalized to
GluA2/3/4 expression, and all other proteins were normalized to b-actin expression. Data
are presented as the immunoreactivity relative to vehicle controls for each protein target,
and treatment effects were measured within single gels (n=3-5/group/gel). The DH and

24

mPFC were analyzed for phosphorylation of p42 and p44 ERK, cofilin, and CaMKIIα, the
ratio of GluA1 to GluA2/3/4, and the total expressions of F-actin, PSD95, SNAP25, c-Fos,
synaptophysin, BDNF, and ERb; the amygdala was analyzed for phosphorylation of p42
and p44 ERK and the total expressions of F-actin, PSD95, c-Fos, synaptophysin, and
BDNF; and the hypothalamus was analyzed for total expression of c-Fos.
Statistical Analyses
Prior to statistical analyses of treatment effects, outliers, assessed as any data points
> 2 standard deviations from the group mean, were removed from each data set. Taskspecific exclusions are described above. Finally, one E2-treated and two DPN-treated
mice were removed prior to the conclusion of the study and euthanized due to declining
health, as indicated by aberrant amounts of barbering or > 5% weight loss between
weeks. Therefore, sample sizes are not equal across all test parameters in each
measurement, although sample sizes are noted in-text.
All statistical tests were conducted using GraphPad Prism 8 (La Jolla, CA). All
anxiety- and depression-like, final TSkin, and Western blot measurements were analyzed
by one-way analysis of variance (ANOVA), followed by Tukey post hoc tests on main
effects of group. Body weight measurements and DTSkin measurements during vehicle
and senktide challenge were analyzed by mixed-effects two-way ANOVA (treatment x
time since OVX, and treatment x time since SC injection, respectively) due to removal of
outliers at individual time points, followed by Tukey post hoc tests. For memory in the OP
and OR tests, two analyses were performed. To assess memory within each group, onesample t tests were used to compare time spent with the moved or novel object,
respectively, to chance (15 s). One-way ANOVAs were conducted to compare treatment
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groups to one another, followed by Tukey’s post hoc tests on main effects of treatment.
Significance was defined at p < 0.05. Effect sizes were calculated as Cohen’s d for
significant t tests and eta squared (h2) for significant ANOVAs.

Results
Long-Term Oral Administration of a Highly Selective ERb Agonist, EGX358, did not
Adversely Affect Overall Health or Body Weight
We first sought to ensure that long-term administration of EGX358 does not cause
adverse health effects, as measured by disheveled physical appearance or premature
death. Young female mice were OVXed (n=40). Following recovery from surgery (Figure
2), mice were gavaged with vehicle (n=10), E2 (n=10), DPN (n=10), or EGX358 (n=10)
for 9 weeks. Throughout the duration of this study, three mice were removed due to
excessive barbering, weight loss, or poor apparent health. Two DPN-treated mice were
removed and euthanized due to weight loss and poor physical appearance, and one E2treated mouse was removed and euthanized due to excessive barbering, but no vehicleor EGX358-treated mice were removed from this study. The lack of poor outcomes in the
EGX358 group suggests that long-term oral administration of EGX358 has no negative
impact on overall health, as observed by physical appearance and measured by weight
status.
Mice were also weighed weekly to adjust treatment volume and measure effects
of long-term treatment with EGX358 on weight gain following OVX, a commonly
documented phenomenon post-OVX that is reduced by E2 when compared to vehicle
treatment (Couse & Korach, 1999; Sibonga et al., 1998). Mixed-effects two-way ANOVA
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(treatment x time since OVX) analysis revealed a significant effect of time (F(4.102, 138.7) =
103.6, p < 0.0001, η2 =
0.8815), but not of treatment
(F(3,

36)

= 0.5673, p =

0.6401). Although the time x
treatment interaction was
significant (F(30, 338) = 1.644,
p = 0.0202, η2 = 0.1023),
Tukey’s
indicated

post

hoc

no

tests

significant

between-group differences
at any time point (Figure 5).
This interaction appears to
be driven by the DPNtreated

group,

which

Figure 5. Long-term treatment with EGX358 did not alter
weight gain following ovariectomy. Young female C57BL/6
mice were bilaterally ovariectomized and given 1 week to recover.
Following recovery, mice began daily oral gavage treatment with
vehicle (10% DMSO; n=10), E2 (n=10), DPN (n=10), or EGX358
(n=10). Daily treatment continued throughout the duration of the
experiment, 64 days in total. Mice were weighed immediately prior
to ovariectomy surgery and at the beginning of every week
thereafter to both adjust treatment volume, as well as examine the
effects of long-term EGX358 treatment on body weight following
ovariectomy. There was a significant increase in body weight over
the course of the experiment (p < 0.0001) that did not significantly
differ among the groups at any time point. DMSO, dimethyl
sulfoxide; E2, 17b-estradiol; DPN, diarylpropionitrile. Error bars
represent mean ± SEM.

weighed somewhat more on average than the other groups beginning 6 weeks post-OVX,
although the lack of significant post hoc analyses shows this to be a rather weak trend.
Collectively, these results suggest that long-term oral EGX358 administration did not
adversely affect overall health, nor did it affect weight gain relative to vehicle treatment.
EGX358, DPN, and E2 Similarly Alleviated an Acute Drug-Induced Increase in Tail Skin
Temperature
Although our group has shown that acute post-training administration of EGX358
promotes memory consolidation in OVX mice (Hanson et al., 2018), we have yet to study
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its effects on other preclinical indices of menopausal symptoms. Here, we aimed to
determine whether long-term oral treatment with EGX358 at the lowest memoryenhancing dose observed in our previous study could reduce hot flash-, anxiety-, and
depression-like symptoms and enhance memory formation. Previous studies have
demonstrated that long-term treatment with E2 or ERb-selective phytoestrogen diets can
prevent increases in TSkin in rats and mice following OVX (Opas et al., 2004; L. Zhao et
al., 2011), and that this effect is seen in ERa knockout mice (Opas et al., 2006). However,
this model does not recapitulate the sudden and transient nature of hot flashes, which are
driven by disrupted neurokinin B signaling in the median preoptic area due to the loss of
circulating estrogens (Padilla et al., 2018; Rance et al., 2013; Tan et al., 2016). A more
recently developed method for vasomotor symptom induction is the administration of a
tachykinin 3 receptor agonist, senktide, which elicits a transient increase in TSkin that is
prevented by chronic E2 administration (Krajewski-Hall et al., 2018; Krull et al., 2017).
Here, we used this method to model hot flash-like symptoms and their treatments.
Sample sizes at the start of the study were n=10/group. As described above and
where appropriate in the following sections, some mice were excluded from data analyses
due to various issues. As such, sample sizes below reflect the number of mice in each
group included in the data analyses. Eleven days after ovariectomy, mice began oral
gavage treatment. After two weeks of treatment, mice gavaged with vehicle, E2, DPN or
EGX358 were then injected SC with vehicle solution 1 h later to determine possible effects
of injection procedures on TSkin (Figures 2, 3). Sample sizes were as follows: vehicle
(n=10), E2 (n=10), DPN (n=7), and EGX358 (n=10). As others have demonstrated that
ambient room temperature affects TSkin in OVX mice (Krajewski-Hall et al., 2018), the
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testing room temperature was measured at the beginning of each test. During testing,
room temperature ranged between 22.0 and
22.5°C. In the vehicle challenge, a modest
and transient increase in TSkin relative to
baseline (DTSkin) was observed immediately
after SC injection that did not significantly
differ between groups (Figure 6A). Mixedeffects two-way ANOVA (treatment x time
since SC injection) revealed a main effect of
time (F(4.731,

154.3)

= 9.169, p < 0.001, η2 =

0.2959), but no main effect of treatment (F(3,
34)

= 1.070, p = 0.3746). Although the time x

treatment interaction was significant (F(69, 750)
= 1.393, p = 0.0227, η2 = 0.6557), Tukey’s
post hoc tests indicated no significant
between-group differences at any time point,
despite modestly higher DTSkin in EGX358treated mice between 5-15 min following SC
injection. These results suggest that the
Figure 6. Legend on next page.

injection process itself caused a modest, but

transient, increase in TSkin that was not significantly influenced by E2 or ERb agonist
treatment.
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Figure 6. Long-term treatment with EGX358 reduced senktide-mediated increases in tail skin
temperature. Following 2 weeks of daily gavage with vehicle (n=10), E2 (n=10), DPN (n=8), or EGX358
(n=10), mice were evaluated in a senktide-mediated model of vasodilation. Mice were tested twice,
once after being injected subcutaneously with 0.9% saline and once after senktide injection, to ensure
that senktide-mediated DTSkin could not be attributed to the injection process. A) Baseline TSkin was
thermally imaged for 10 min, after which mice were injected subcutaneously with 0.9% saline and then
were imaged for another 20 min. Compared to the baseline TSkin measured 2.5 min prior to injection,
subcutaneous injection caused a modest increase in TSkin that returned to baseline within 20 min in all
treatment groups (p < 0.0001). An interaction between treatment and time since injection (p = 0.0227)
was observed, such that EGX358-treated mice tended be modestly warmer than other mice at 5-15
min post-injection, although post hoc analyses revealed no significant differences between treatment
groups at any time point. B) In all treatment groups, subcutaneous injection of senktide caused a
transient, significant increase in TSkin compared to baseline (p < 0.0001). However, an effect of
treatment (p = 0.0041) and an interaction between treatment and time since injection (p < 0.0001) were
observed. E2, DPN, and EGX358 reduced DTSkin due to injection compared to vehicle, such that E2treated mice had significantly lower DTSkin compared to vehicle-treated mice 3-5, 8-12, and 19 min postinjection (blue lines, *p < 0.05); DPN-treated mice had significantly lower DTSkin compared to vehicle 811, 13, and 19 min post-injection (green lines, *p < 0.05); and EGX358-treated mice had significantly
lower DTSkin due to injection compared to vehicle 5-9, 16, and 19 min post-injection (red lines, *p <
0.05). C) TSkin was measured on the final day of the experiment to determine the effects of long-term
treatment on baseline TSkin. E2-treated mice had significantly lower TSkin compared to vehicle-treated
mice after 63 days of treatment (p = 0.0221). E2, 17b-estradiol; DPN, diarylpropionitrile; TSkin, tail skin
temperature; DTSkin, change in tail skin temperature relative to baseline. Error bars represent mean ±
SEM. *p < 0.05, compared to vehicle.

Four days later, mice were gavaged and injected SC with senktide 1 h later
(Figures 2, 3). Again, room temperature was measured at the beginning of each senktide
test, ranging between 21.4 and 22.1°C. Mixed-effects two-way ANOVA (treatment x time
since injection) revealed main effects of time (F(6.052, 188.4) = 147.7, p < 0.0001, η2 = 0.8560)
and treatment (F(3, 32) = 5.381, p = 0.0041, η2 = 0.0155), and a time x treatment interaction
(F(69, 716) = 1.895, p < 0.0001, η2 = 0.1252; Figure 6B). Post hoc tests revealed that E2treated mice had significantly reduced DTSkin (change in Tskin relative to pre-injection
baseline TSkin) compared to vehicle-treated mice 3-5, 8-12, and 19 min post-injection (p <
0.05). DPN significantly reduced DTSkin compared to vehicle 8-11, 13, and 19 min postinjection (p < 0.05). Finally, EGX358 significantly reduced DTSkin compared to vehicle 59, 16, and 19 min post-injection (p < 0.05). No significant differences among the E2, DPN,
or EGX358 groups were revealed at any time point in this test. These results demonstrate
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similarly beneficial efficacy of E2, DPN, and EGX358 in reducing vasodilation induced by
activation of neurokinin B receptors.
Finally, we examined whether long-term treatment could prevent the gradual
increase in TSkin associated with long-term OVX (Opas et al., 2004; Rance et al., 2013; L.
Zhao et al., 2011). The day following completion of OR testing (day 63 of treatment), mice
were gavaged and thermally imaged in their home cages 1 h later (Figures 2, 3). Sample
sizes were as follows: vehicle (n=9), E2 (n=8), DPN (n=8), and EGX358 (n=10).
Throughout treatment and imaging, the temperature of the colony room in which
observations were made was measured and ranged between 23.3 and 23.8°C. One-way
ANOVA revealed a significant effect of treatment on baseline TSkin (F(3, 31) = 3.691, p =
0.0221, η2 = 0.2632; Figure 6C), with post hoc analyses showing that only E2-treated mice
had significantly lower baseline TSkin compared to vehicle-treated mice (p < 0.05).
Collectively, our results indicate that a relatively low dose of EGX358 reduced
transient increases in tail skin vasodilation induced by neurokinin B signaling to similar
extents as E2 and DPN. However, only E2, but not ERb agonists alone, reduced baseline
TSkin when compared to vehicle treatment.
EGX358 and Other Estrogenic Compounds did not Affect Anxiety-like or Locomotor
Behaviors
Long-term OVX in rats and mice is associated with increased anxiety-like
behaviors when compared to sham-operated controls, and these behaviors are reduced
by systemic administration of estrogenic compounds, including E2 and DPN, relative to
vehicle treatment (Frye and Walf, 2004; Lagunas et al., 2010; Li et al., 2014; Lund et al.,
2005; Oyola et al., 2012; Walf and Frye, 2006, 2005b). Therefore, we next sought to
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determine the effects of EGX358 on anxiety-like behaviors. The day after completion of
the senktide tail vasodilation test (day 23 of treatment), mice were gavaged with vehicle
(n=10), E2 (n=10), DPN (n=8), or EGX358 (n=10) (Figures 2, 3). One hour later, mice
were placed into an empty OF box and the time, distance traveled, fecal boli, and entries
in the outer, middle, and center zones were recorded. One-way ANOVAs revealed no
significant treatment effects for fecal boli in the outer, middle, and center zones or for total
fecal boli (Table 1). Similarly, total distance traveled, distance in the outer, middle, and
center zones, and entries into the outer, middle, and center zones did not differ
significantly among the groups (Table 1). Although the groups did not differ in time spent
in the outer or middle zones, the treatment effect was significant for time spent in the
center zone (F(3, 33) = 4.269, p = 0.0118, η2 = 0.2796; Table 1). Post hoc analysis revealed
that E2-treated mice spent significantly more time in the center zone than all other
treatment groups (all p values < 0.05).
We also measured time and bouts spent grooming/barbering and rearing. The
main effect of treatment was significant for time spent grooming/barbering (F(3, 31) =
3.506, p = 0.0268, η2 = 0.2534; Table 1). Although post hoc tests did not indicate
significant differences between any of the treatment groups, the treatment effect may
have been driven by modestly reduced time grooming/barbering in E2- and EGX358treated mice relative to vehicle- and DPN-treated mice. The groups also differed
significantly in time spent rearing (F(3, 33) = 4.278, p = 0.0117, η2 = 0.2800; Table 1), due
to increased rearing in E2-treated mice relative to vehicle. No significant effects of
treatment were observed for bouts of grooming/barbering or rearing (Table 1).
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Next, we measured the effects of long-term treatment on anxiety-like behaviors in
the EPM. One day after completion of the OF test (day 25 of treatment), mice were
gavaged with vehicle (n=10), E2 (n=10), DPN (n=8), or EGX358 (n=9) and were placed
into the EPM apparatus one hour later (Figures 2, 3). For data analysis, the EPM was
divided into three zones: open arms, closed arms, and center. The time spent, number of
entries, and number of fecal boli in each zone was recorded, as were total entries into all
zones and total boli. However, no treatment differences were observed in any of these
measures (Table 1). We also assessed “peeking” behavior by quantifying the number of
peeking bouts and time spent peeking into the open arms or over the edge of the
apparatus. As with the other EPM measures, no significant treatment differences were
observed in either of these measurements (Table 1).
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Together, our results also suggest a modest anxiolytic effect of long-term oral E2
treatment, but not ERb agonism, at least at the doses tested, in young ovariectomized
mice. Additionally, our results suggest no effect of E2 treatment or ERb agonism on
locomotor behaviors.
EGX358 and Other Estrogenic Compounds did not Affect Depression-Like Behaviors
As with anxiety-like behaviors, previous research indicates that OVX mice and rats
display greater depression-like behaviors when compared to sham-operated controls,
and that these behaviors are reduced by administration of estrogenic compounds,
including E2 and DPN, compared to vehicle treatment (Li et al., 2014; Rocha et al., 2005;
Walf et al., 2004; Walf & Frye, 2006, 2007). Therefore, we next examined potential effects
of long-term EGX358 treatment on depression-like behaviors in the TST and FST. One
day following completion of EPM testing (day 27 of treatment), mice were gavaged with
vehicle (n=10), E2 (n=10), DPN (n=8), or EGX358 (n=10) and were suspended by their
tails one hour later (Figures 2, 3). The time spent immobile, latency to first bout of
immobility, and number of fecal boli produced were recorded. One-way ANOVAs revealed
no significant treatment effects on any measure (Table 2). The next day (day 30 of
treatment), mice were gavaged and placed into the FST cylinder one hour later. As in the
TST, time spent immobile, latency to first bout of immobility, and number of fecal boli were
recorded. Similar to the TST, no treatment effects were significant for any measure (Table
2). Collectively, these findings suggest that long-term EGX358 treatment at the current
dose does not affect depression-like behaviors in a mouse model of menopause.
These findings suggest no effect of long-term oral E2 treatment or ERb agonism,
at least at the doses tested, on depression-like behaviors in young ovariectomized mice.
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EGX358 Enhanced Both Spatial and Object Recognition Memory
Our laboratory has previously demonstrated that a single post-training
intraperitoneal (i.p.) injection of E2 enhances spatial memory consolidation in the Morris
water maze and recognition memory consolidation in OR (Gresack & Frick, 2006b), and
that a single post-training administration (i.p. injection or oral gavage) of DPN or EGX358
enhances memory consolidation in both OR and OP in young ovariectomized mice
(Hanson et al., 2018). Here, we aimed to determine whether long-term daily gavage of
these compounds at the same doses would enhance memory in the OP and OR tasks.
OP training and testing began on day 41 of treatment and OR training and testing started
on day 52 of treatment (Figures 2, 3).
One hour prior to OP training, mice were gavaged with vehicle (n=10), E2 (n=9),
DPN (n=7), or EGX358 (n=8) (Figure 3). Twenty-three hours later, mice were again
gavaged with their respective treatments and tested one hour later. Learning within a
group was demonstrated with one-sample t-tests, which revealed that mice receiving E2
(t(8) = 2.320, p = 0.0489, d = 0.7728; Figure 7A), DPN (t(6) = 4.266, p = 0.0053, d = 1.6138),
or EGX358 (t(7) = 3.117, p = 0.0169, d = 1.1026) spent significantly more time than chance
(15 s) with the moved object, whereas vehicle-treated mice did not (t(9) = 1.654, p =
0.1326). Although a one-way ANOVA revealed no main effect of treatment (F(3, 30) = 1.710,
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p = 0.186), the pattern of within-group learning suggests that long-term treatment with E2,
DPN, or EGX358 enhanced spatial memory formation in the OP task.
OR was conducted similarly, except that the delay between training and testing
was 48 hours instead of 24 hours, requiring mice to be gavaged with vehicle (n=9), E2
(n=9), DPN (n=7), or EGX358 (n=10) three times: one hour prior to training, and again
twenty-three and forty-seven hours later
(Figure 3). Mice were tested one hour after the
third gavage. One-sample t-tests revealed that
whereas E2- (t(8) = 2.439, p = 0.0406, d =
0.8128) and EGX358-treated (t(9) = 4.342, p =
0.0019, d = 1.3732; Figure 7B) mice spent
more time than chance with the novel object,
vehicle- (t(8) = 1.045, p = 0.3267) and DPNtreated (t(6) = 2.400, p = 0.0533) mice did not.
Although the DPN group mean was similar to
that for EGX358, its variability was higher,
likely due to its smaller sample size. Again, the
main effect of treatment was not significant (F(3,
Figure 7. Long-term treatment with EGX358 enhanced spatial and object recognition memory.
Following completion of forced swim testing, mice continued daily gavage of vehicle (n=10), E2 (n=9),
DPN (n=8), or EGX358 (n=10) without being tested for 7-8 days, after which they began training and
testing in OP and, subsequently, OR. A) Mice were gavaged 1 hour prior to training and testing phases
of the OP task. Mice treated with E2, DPN, or EGX358, but not vehicle, spent significantly more time
than chance (dashed line at 15 s) with the moved object during the testing phase of OP. B) Similar to
OP, mice gavaged with E2 or EGX358 1 hour prior to training, 24 hours later, and 1 hour prior to testing
spent significantly more time than chance with the novel object during the testing phase of OR. E2,
17b-estradiol; DPN, diarylpropionitrile; OP, object placement; OR, object recognition. Error bars
represent mean ± SEM. *p < 0.05, compared to chance.
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31)

= 0.6365, p = 0.5972), but the within-subjects analyses suggest that long-term E2 or

EGX358 treatment enhanced object recognition memory.
Together, these findings suggest that long-term oral gavage of E2 and EGX358
enhances spatial and object recognition memory in young ovariectomized mice, with DPN
providing some similar benefits.
Long-Term EGX358 Treatment did not Affect Protein Activation or Expression in the DH,
mPFC, Amygdala, or Hypothalamus
Given our physiological and behavioral results demonstrating that long-term oral
treatment with E2, DPN, and EGX358 reduce drug-induced increases in vasodilation and
enhance memory, and that E2 treatment modestly alleviates anxiety-like behaviors, we
next wished to examine the molecular effects of these treatments in ERb-laden brain
regions implicated in memory, affective symptoms, and hot flashes. Therefore, the day
after the final tail skin temperature measurement, mice were gavaged with vehicle (n=10),
E2 (n=9), DPN (n=8), or EGX358 (n=10) and euthanized 30 min later (Figure 4). Tissues
from the DH, mPFC, amygdala, and hypothalamus were collected rapidly on wet ice for
subsequent Western blot analyses.
We and others have demonstrated repeatedly that acute or long-term 17b-estradiol
and DPN treatment promotes cell signaling, the activation of plasticity-mediating kinases
and trophic factors, such as the p42 isoform of ERK and BDNF, and increases in dendritic
spine densities in the DH in rodents, which are associated with better memory outcomes
(Boulware et al., 2013; Fernandez et al., 2008; Inagaki et al., 2012; Jain et al., 2019; Y.
Zhao et al., 2017). Although less is known about the actions of estrogenic signaling in the
mPFC, similar activation and spine density changes are seen therein following acute or

37

long-term treatment with E2 and phytoestrogens (Inagaki et al., 2012; Pan et al., 1999;
Zeidan et al., 2011). Furthermore, estrogenic signaling appears to reduce activity in both
the amygdala and median preoptic area of the hypothalamus, which appear to mediate
the anxiolytic, anti-depressive, and vasodilation-reducing effects of estrogens (Dacks et
al., 2011; Zeidan et al., 2011). Therefore, regional homogenates were blotted for phospop42 and phospho-p44 ERK, phospho-CaMKIIα, phospho-cofilin, the ratio of GluA1 to
GluA2/3/4, and/or the total expressions of F-actin, PSD95, SNAP25, c-Fos,
synaptophysin, BDNF, and ERb relative to b-actin expression, depending on the region
being analyzed. Specifically, we hypothesized that in regions highly implicated in learning
and memory outcomes, namely the DH and mPFC, long-term treatment with E2, DPN,
and EGX358 would increase markers of cellular activity (c-Fos), phosphorylation of rapid
kinases critical for learning and memory outcomes (p42 ERK and CaMKIIα), trophic
factors critical for learning and memory outcomes (BDNF), presynaptic markers of
vesicular release of neurotransmitters (SNAP25, synaptophysin), postsynaptic markers
of plasticity (PSD95, GluA ratio), and postsynaptic markers of actin remodeling (F-actin,
phospho-cofilin), and prevent a decline in sensitivity to treatment (ERb) to reflect memory
outcomes. In the amygdala, a region highly associated with affective outcome, we
hypothesized E2, DPN, and EGX358 treatment would lower expression of c-Fos,
phospho-p42 ERK, BDNF, synaptophysin, PSD95, and F-actin, reflecting our anxiety-like
measurements. Finally, given that all three treatments reduced drug-induced vasomotor
symptoms relative to vehicle, and E2 prevented a rise in baseline TSkin, we hypothesized
that they would reduce c-Fos expression in the hypothalamus compared to vehicle
treatment.
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Surprisingly, and in contrast to their memory-enhancing effects, E2, DPN, and

Figure 8. Figure legend on next page.

EGX358 did not alter protein expression or phosphorylation of any target proteins in the
DH (Figure 8A). Namely, there were no significant main effects of treatment in the DH on
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Figure 8. Long-term EGX358 treatment does not affect protein expression or phosphorylation
in the dorsal hippocampus. The day following completion of all behavioral and physiological
measurements, mice were gavaged with vehicle (n=10), E2 (n=9), DPN (n=8), or EGX358 (n=10). Mice
were euthanized 30 min later, and DH tissue was collected for Western blot analysis. A) Representative
images proteins blotted. No treatment effects were found in expressions of B) c-Fos, F) BDNF, G)
synaptophysin, H) SNAP25, I) PSD95, or K) F-actin, phosphorylation levels of C) 42kDa ERK, D)
44kDa ERK, E) CaMKIIa, or J) cofilin, or L) the ratio of GluA1:GluA2/3/4. M) Additionally, there were
no differences in ERb expression due to treatment. DH, dorsal hippocampus; ERK, extracellular signalregulated kinase; CaMKII, calcium/calmodulin-dependent kinase II; BDNF, brain-derived neurotrophic
factor; PSD95, postsynaptic density protein 95; F-actin, filamentous actin; GluA, AMPA receptor
subunit; ERb, estrogen receptor b; E2, 17b-estradiol; DPN, diarylpropionitrile. Error bars represent
mean ± SEM. All p > 0.05.

the phosphorylation of the 42kDa (F(3, 31) = 0.8945, p = 0.4550, Figure 8C) or 44kDa
isoforms of ERK (F(3, 32) = 1.240, p = 0.2967, Figure 8D), CaMKIIα (F(3, 33) = 0.3678, p =
0.7767, Figure 8E), or cofilin (F(3, 32) = 2.126, p = 0.1151, Figure 8J), the expressions of
c-Fos (F(3, 31) = 0.3950, p = 0.7575, Figure 8B), BDNF (F(3, 32) = 1.444, p = 0.2483, Figure
8F), synaptophysin (F(3, 32) = 0.3665, p = 0.7776 Figure 8G), SNAP25 (F(3, 32) = 1.485, p
= 0.2373, Figure 8H), PSD95 (F(3, 32) = 1.572, p = 0.2154, Figure 8I), or F-actin (F(3, 33) =
0.2525, p = 0.8589, Figure 8K), or the ratio of GluA1:GluA2/3/4 (F(3, 33) = 0.6963, p =
0.5610, Figure 8L). Importantly, these results cannot be accounted for by the alteration
of ERb levels, as there were no differences in ERb expression among treatment groups
here (F(3, 33) = 0.9581, p = 0.4240, Figure 8M).
As in the DH, surprisingly, there were no treatment effects on protein expression
or phosphorylation in the mPFC (Figure 9A). Namely, there were no significant treatment
effects in the mPFC on the phosphorylation of the 42kDa (F(3, 32) = 0.5117, p = 0.6771,
Figure 9C) or 44kDa isoforms of ERK (F(3, 32) = 1.191, p = 0.3289, Figure 9D), CaMKIIα
(F(3, 30) = 0.9709, p = 0.4194, Figure 9E), or cofilin (F(3, 31) = 1.223, p = 0.3179, Figure 9J),
the expressions of c-Fos (F(3, 30) = 0.1704, p = 0.9155, Figure 9B), BDNF (F(3, 30) = 0.7244,
p = 0.5454, Figure 9F), synaptophysin (F(3, 32) = 0.3573, p = 0.7842, Figure 9G), SNAP25
(F(3, 31) = 0.8423, p = 0.4812, Figure 9H), PSD95 (F(3, 31) = 1.063, p = 0.3791, Figure 9I),
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Figure 9. Figure legend on next page.

or F-actin (F(3, 30) = 1.190, p = 0.3301, Figure 9K), or the ratio of GluA1:GluA2/3/4 (F(3, 32)
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Figure 9. Long-term EGX358 treatment does not affect protein expression or phosphorylation
in the medial prefrontal cortex. The day following completion of all behavioral and physiological
measurements, mice were gavaged with vehicle (n=9), E2 (n=9), DPN (n=8), or EGX358 (n=10). Mice
were euthanized 30 min later, and mPFC tissue was collected for Western blot analysis. A)
Representative images proteins blotted. No treatment effects were found in expressions of B) c-Fos,
F) BDNF, G) synaptophysin, H) SNAP25, I) PSD95, or K) F-actin, phosphorylation levels of C) 42kDa
ERK, D) 44kDa ERK, E) CaMKIIa, or J) cofilin, or L) the ratio of GluA1:GluA2/3/4. M) Additionally,
there were no differences in ERb expression due to treatment. PFC, prefrontal cortex; ERK,
extracellular signal-regulated kinase; CaMKII, calcium/calmodulin-dependent kinase II; BDNF, brainderived neurotrophic factor; PSD95, postsynaptic density protein 95; F-actin, filamentous actin; GluA,
AMPA receptor subunit; ERb, estrogen receptor b; E2, 17b-estradiol; DPN, diarylpropionitrile. Error
bars represent mean ± SEM. All p > 0.05.

= 0.4939, p = 0.6890, Figure 9L). Similar to the DH, these findings cannot be explained
by differences in ERb levels, as there were no treatment effects on ERb expression (F(3,
31)

= 0.1581, p = 0.9236, Figure 9M).
Perhaps unsurprisingly, given the modest anxiety- and depression-like behavioral

results, long-term treatment with E2, DPN, or EGX358 did not alter protein expression or
phosphorylation in the amygdala (Figure 10A). Namely, there were no treatment effects
in the amygdala on the phosphorylation of the 42kDa (F(3, 32) = 0.4723), p = 0.7037, Figure
10C) or 44kDa isoforms of ERK (F(3,

32)

= 0.8206, p = 0.4921, Figure 10D) or the

expressions of c-Fos (F(3, 31) = 0.6774, p = 0.5725, Figure 10B), BDNF (F(3, 32) = 0.9996,
p = 0.4057, Figure 10E), synaptophysin (F(3, 31) = 1.461, p = 0.2443, Figure 10F), PSD95
(F(3, 33) = 0.4471, p = 0.7210, Figure 10G), or F-actin (F(3, 32) = 0.9908, p = 0.4096, Figure
10H).
Finally, given the reduction in drug-induced vasodilation due to estrogenic
treatment and the lower baseline temperature noted after 63 days of E2 treatment relative
to vehicle treatment, it was also surprising to find no treatment effects on c-Fos expression
in the hypothalamus (F(3, 33) = 0.07415, p = 0.9735, Figure 11A, B).
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Figure 10. Long-term EGX358 treatment does not affect protein expression or phosphorylation
in the amygdala. The day following completion of all behavioral and physiological measurements,
mice were gavaged with vehicle (n=10), E2 (n=9), DPN (n=8), or EGX358 (n=10). Mice were
euthanized 30 min later, and amygdala tissue was collected for Western blot analysis. A)
Representative images proteins blotted. No treatment effects were found in expressions of B) c-Fos,
E) BDNF, F) synaptophysin, G) PSD95, or H) F-actin or phosphorylation levels of C) 42kDa ERK, D)
44kDa ERK. ERK, extracellular signal-regulated kinase; BDNF, brain-derived neurotrophic factor;
PSD95, postsynaptic density protein 95; F-actin, filamentous actin; E2, 17b-estradiol; DPN,
diarylpropionitrile. Error bars represent mean ± SEM. All p > 0.05.

Discussion
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We and others have previously demonstrated roles for ERb signaling in enhancing
memory processes, reducing anxiety- and depression-like behaviors, and reducing
vasomotor symptoms in OVX rodents (Boulware et al., 2013; Hanson et al., 2018; Jacome
et al., 2010; J. Kim & Frick, 2017; Li et al., 2014; Lund et al., 2005; Opas et al., 2006;
Oyola et al., 2012; Pereira et al., 2014; Rocha et al.,
2005; Walf et al., 2004, 2006, 2008; Walf & Frye,
2005; L. Zhao et al., 2011). However, the present
study is the first to examine the effects of long-term
oral ERb agonist treatment on preclinical indices of
menopausal symptoms in OVX mice. This work is
particularly notable for its evaluation of EGX358,
which is 750-fold more selective for ERb over ERa
Figure 10. Long-term EGX358
treatment does not affect c-Fos in
the hypothalamus. The day
following completion of all behavioral
and physiological measurements,
mice were gavaged with vehicle
(n=10), E2 (n=9), DPN (n=8), or
EGX358
(n=10).
Mice
were
euthanized 30 min later, and
hypothalamic tissue was collected
for Western blot analysis. A)
Representative images proteins
blotted. B) No treatment effects were
found in expression of c-Fos. E2,
17b-estradiol;
DPN,
diarylpropionitrile.
Error
bars
represent mean ± SEM. p > 0.05.

and is therefore the most selective ERb synthetic
agonist available to date (Hanson et al., 2018).
Here, we showed that daily gavage of EGX358,
DPN, and E2 reduced senktide-induced increases in
TSkin after ~2.5 weeks of treatment, and 9 weeks of
E2, but not ERb agonist alone, treatment reduced
TSkin compared to vehicle treatment. Next, we
demonstrated that, although EGX358, DPN, and E2

had largely no effects on anxiety- or depression-like behaviors, daily gavage for 8-9
weeks enhanced spatial and object recognition memory in the OP and OR tasks.
Surprisingly, there were no effects of 64 days of E2, DPN, or EGX358 treatment on
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cellular activity- and synaptic plasticity-related protein expression or phosphorylation in
the DH, mPFC, amygdala, or hypothalamus, regions which are all highly implicated in
learning and memory outcomes, affective symptom presentation, and hot flash mediation.
Importantly, long-term oral administration of EGX358 did not result in premature death or
adverse health effects in any mice, although estrogenic treatment also failed to prevent
weight gain compared to vehicle. Collectively, these results provide promising evidence
that long-term administration of selective ERb agonists like EGX358 may be effective
treatment options for some menopausal symptoms, although the cellular and molecular
mechanisms underlying EGX358’s behavioral and physiological effects remain to be
determined.
Effects on Vasodilation
Our data showing that both DPN and our novel, highly selective ERb agonist,
EGX358, prevent senktide-mediated increases in TSkin are the first to demonstrate a role
for ERb activation in this model. Previous findings have demonstrated that systemic
senktide administration produces rapid, transient increases in TSkin in male and gonadallyintact and OVX female mice (Krajewski-Hall et al., 2018; Krull et al., 2017). These effects
are mediated by the binding of senktide to tachykinin 3 receptors in the median preoptic
area of the hypothalamus, thereby activating warm-sensitive neurons in this region and
initiating vasodilation and cold-seeking behaviors in rodents (Krull et al., 2017; MittelmanSmith et al., 2015; Padilla et al., 2018; Rance et al., 2013; Tan et al., 2016). Importantly,
previous studies have also demonstrated that tachykinin 3 receptor-mediated tail
vasodilation responses are reduced in intact compared to OVX female mice and following
senktide administration in OVX mice treated chronically with E2 via silastic capsule
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compared to vehicle-treated mice (Krajewski-Hall et al., 2018; Padilla et al., 2018). We
add to this growing body of literature by demonstrating that long-term treatment with ERb
agonists can mitigate senktide-induced increases in TSkin. Importantly, E2 (0.2 mg/kg),
DPN (0.05 mg/kg), and EGX358 (0.5 mg/kg) all prevented senktide-mediated changes in
TSkin compared to vehicle treatment, suggesting a protective role of ERb signaling against
neurokinin B-mediated hot flash symptoms. Although TSkin increased modestly and
transiently after vehicle injection, it is highly unlikely that this increase influenced the
effects of estrogenic compounds on TSkin. Importantly, the DTSkin increase following
senktide injection was more than 2-fold higher than after vehicle injection, with DTSkin of
under 2oC after vehicle injection and of 4-5oC after senktide injection. Additionally, only
senktide-treated mice exhibited characteristic tail rattles and expressed cold-seeking
behaviors, such as moving cage bedding around to create bare, cool spots, where they
would reside for much of the test, behaviors that were unaffected by estrogenic compound
treatment. Others have made similar observations following senktide treatment in mice
(Krajewski-Hall et al., 2018; Krull et al., 2017). These quantitative and qualitative
differences suggest that the estrogenic compounds specifically mitigated the vasodilatory
response to senktide, not a more general reaction to the injection procedure. As such,
our data indicate that long-term oral treatment with E2 or ERb agonists such as EGX358
can reduce vasodilation in a neurokinin B-mediated model of hot flashes.
Interestingly, nine weeks of ERb agonist treatment did not affect baseline TSkin. Longterm OVX is a common method for modeling vasomotor symptoms and their treatment in
rodents, as this surgical method induces gradual increases in tail vasodilation, and
chronic treatment with estrogenic compounds often prevents this elevation in temperature
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in both mice and rats (Berendsen et al., 2001; Bowe et al., 2006; Dacks & Rance, 2010;
Kobayashi et al., 1995; Opas et al., 2004, 2006; L. Zhao et al., 2011). We recapitulate
these findings by demonstrating that E2 (0.2 mg/kg) administered for 9 weeks via gavage
reduces baseline TSkin in OVX mice relative to vehicle-treated mice. However, DPN (0.05
mg/kg) and EGX358 (0.5 mg/kg) treatment did not alter TSkin relative to vehicle treatment
at this time point. These findings contrast with previous studies demonstrating that ERbselective phytoestrogen diets and DPN injections can reduce increases in TSkin compared
to vehicle treatment following OVX in both rats and mice (Bowe et al., 2006; Opas et al.,
2006; L. Zhao et al., 2011). However, the long-term design of our study, in addition to the
relatively low dosage of both DPN and EGX358, may have contributed to these
contrasting results. For example, Bowe et al. (2006) showed that four days of
subcutaneous injections of DPN at 0.6 mg/kg, a dose twelve-fold greater than that
administered here, lowered DTSkin relative to first-day measurements compared to
vehicle-treated OVX rats. As our chosen EGX358 dose is proportional to our DPN dose,
based upon the previously established relative potency of the compounds, a higher dose
of EGX358 may have more effectively lowered DTSkin relative to vehicle treatment
(Hanson et al., 2018). Additionally, previous studies have demonstrated that TSkin is a
circadian rhythm, and that sensitivity to treatment with estrogenic compounds may be
higher during the dark-phase than the light-phase (Girbig et al., 2012; Williams et al.,
2010). As our measurements were made during the light-phase and only at the end of the
study, it is possible that effects of long-term EGX358 treatment on baseline TSkin may
have been missed or obscured. Follow-up studies utilizing higher ERb agonist doses,
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testing multiple times throughout the study, and/or testing during the dark-phase may
prove useful in demonstrating these effects.
Effects on Anxiety- and Depression-Like Behaviors
Previous research has repeatedly demonstrated an important role for ERb activation
in reducing anxiety- and depression-like behaviors in OVX mice and rats (Frye and Walf,
2004; Lagunas et al., 2010; Li et al., 2014; Lund et al., 2005; Oyola et al., 2012; Rocha et
al., 2005; Walf and Frye, 2007, 2005b, 2004). Surprisingly, the present study showed only
an effect of E2 treatment on time in the center of and time spent rearing in the OF, but no
other effects of any treatment in the OF, EPM, TST, or FST compared to vehicle. This
discrepency, especially given the lack of effects of either ERb agonist, could be due to a
number of factors. Previous studies have shown that sensitivity to estrogenic compounds
in these tasks is highly dependent upon dose, injection schedule, solvent used, and
administration route (as reviewed in Walf & Frye, 2006). As discussed previously, we
selected doses of E2, DPN, and EGX358 which had previously been shown to enhance
memory consolidation in the Morris water maze, OP, and OR tasks when administered
acutely in OVX mice (Gresack and Frick, 2006; Hanson et al., 2018). Although 0.2 mg/kg
E2 should produce physiological levels of E2 when administered via i.p. injection, we
cannot be sure of these levels after oral gavage (Akinci & Johnston, 1997; Gresack &
Frick, 2006b). Additionally, 0.05 mg/kg DPN and 0.5 mg/kg EGX358 are relatively low
compared to other studies in which 0.1-1.0 mg/kg DPN produced anxiolytic and antidepressive effects (Eid et al., 2020; Lund et al., 2005; Oyola et al., 2012). Thus, future
studies will be necessary to determine whether higher doses of daily administered
EGX358 or DPN reduce anxiety- and depression-like behaviors in these tasks.
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Other factors to take into consideration include stress, administration route, and
duration of treatment. A recent study demonstrated that daily subcutaneous injections of
E2 (0.04 mg/kg), DPN (0.1 mg/kg), or the commercially available ERa agonist PPT (0.1
mg/kg) for 47 days in OVX mice all reduce time spent immobile in the TST, but that
chronic unpredictable stress reverses these effects, such that DPN and PPT both
increase time spent immobile in this task (Eid et al., 2020). These data suggest that
elevated stress may block or even reverse the effects of estrogenic compounds on
measures of anxiety- and depression-like behaviors. Although gavage is a more effective
method of ensuring accurate oral dosing than water- or food-based delivery, it is also
more invasive and stressful than these other methods (Machholz et al., 2012). Therefore,
the stress associated with gavage, combined with the relatively low doses used, may
have prevented E2, DPN, and EGX358 from influencing affective measures. Finally, ours
is one of the longest-term studies examining the effects of ERb agonist treatment on
anxiety- and depression-like behaviors in OVX mice. Previous work found that 3-7 days
is optimal for detecting anxiolytic and anti-depressive effects of E2 in both OVX rats and
mice, and most studies demonstrating anxiolytic and anti-depressive actions of DPN in
OVX rodents have administered the compound acutely or for up to 7 days (Bernardi et
al., 1989; Koss et al., 2004; Li et al., 2014; V. N. Luine et al., 1998; Lund et al., 2005;
Oyola et al., 2012; Rocha et al., 2005; Walf et al., 2004; Walf & Frye, 2005, 2006). Thus,
long-term ERb agonist treatment may be less effective than short-term treatment in
mitigating affective behaviors in OVX rodents. Future studies examining putative
influences of dose, route of administration, treatment duration, and stress effects will be
necessary to more fully understand the extent to which daily oral administration of
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estrogenic compounds influences affective behaviors. Importantly, however, none of our
treatments increased anxiety- and depression-like behaviors in any of our tasks,
suggesting that anxiety- or depression-like behaviors are not side effects of long-term E2,
DPN, or EGX358 treatment.
Effects on Memory
Our results demonstrating that long-term oral EGX358 administration in OVX mice
promotes spatial and object recognition memory formation in the OP and OR tasks fits
well with previous results from our lab and others showing memory-enhancing effects of
acute post-training ERb agonism (Boulware et al., 2013; Hanson et al., 2018; Jacome et
al., 2010; Pereira et al., 2014; Said et al., 2018; Walf et al., 2008; L. Zhao et al., 2011).
Whereas many previous studies have demonstrated that a single post-training delivery of
DPN either systemically or directly into the hippocampus enhances OP and OR memory
consolidation in young OVX rats and mice, and that 2 days of pre-training systemic
injections recapitulates these effects, the current study is one of few to demonstrate that
long-term administration of ERb agonists enhance memory (Boulware et al., 2013;
Hanson et al., 2018; Jacome et al., 2010; Pereira et al., 2014; Walf et al., 2008).
Previously, Zhao et al. (2011) demonstrated that treating OVX mice with an ERb-selective
phytoestrogen diet for 9 months enhanced spatial working memory in the Y-maze, and
Said et al. (2018) reported that diet-based DPN treatment (~3.0 mg/kg/day) for 22 months
enhanced spatial memory in the Barnes maze in OVX mice. Thus, the fact that EGX358,
and to a lesser extent DPN, enhanced memory in the present study is consistent with
previous reports of long-term ERb agonist treatment.
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We previously showed that acute DPN or EGX358 treatment given immediately posttraining enhances OP and OR memory consolidation in young OVX mice (Hanson et al.,
2018). These effects were observed after bilateral dorsal hippocampal infusion (DPN: 10
pg; EGX358: 100 pg and 1 ng), or systemic administration via i.p. injection or oral gavage
(DPN: 0.05 mg/kg; EGX358: 0.5 mg/kg or 5 mg/kg) (Hanson et al., 2018). The present
study adds to these findings by showing that long-term oral treatment of either DPN or
EGX358 via gavage enhances spatial and object recognition memory in OVX mice.
Although DPN treatment did not significantly enhance OR consolidation, there was a
trend for such an effect that may have been revealed with an increased sample size.
Although this study was designed to determine effects of long-term treatment on
memory and other factors, it is important to note that our effects on memory could be due
not only to long-term treatment, but also to acute effects of treatment given one hour prior
to training and testing. Given our study design, we cannot necessarily exclude acute
effects in the improvements seen here. However, it is noteworthy that daily oral treatment
with DPN or EGX358 enhanced memory in these tasks to a similar extent as our previous
acute studies (Hanson et al., 2018). Namely, here, we demonstrate that long-term
treatment with DPN or EGX358 promoted time spent with the moved object in OP, such
that DPN treatment and EGX358 treatment resulted in 36.6% and 24.9% more time with
the moved object than chance. Additionally, long-term treatment increased time with the
novel object in the OR task, such that DPN treatment and EGX358 treatment resulted in
20.7% and 19.6% more time spent investigating the novel object than chance. These
findings are similar to our previous report, showing that acute gavage treatment of DPN
and EGX358 resulted in 29.2% and 31.5% more time with the moved object in the OP
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task, and 30.7% and 29.9% more time with the novel object in the OR task (Hanson et
al., 2018). It is interesting that there appears to be a slightly weaker effect of long-term
treatment compared to acute treatment, although this could be due to a number of factors,
including treatment timing, stress of repeated gavage, or time of testing relative to OVX
surgery (1-2 weeks post-surgery in the acute study (Hanson et al., 2018) as compared to
~10 weeks, here). Although we have not tested effects of acute treatment on anxiety-like,
depression-like, or vasomotor symptoms, we would expect similarly slight differences
between acute and long-term administration in each of these measurements. Despite the
minor difference between effect sizes of acute and long-term treatments, our finding that
long-term oral treatment with our highly selective ERb agonist, EGX358, enhanced
memory consolidation in both OP and OR further lends support for its continued
development as an ERb-selective HT for menopause-related memory dysfunction.
Effects on Protein Expression and Phosphorylation
Surprisingly, long-term administration of E2, DPN, or EGX358 did not affect
expression or phosphorylation of protein markers of cellular activity or synaptic plasticity
in the DH, mPFC, amygdala, or hypothalamus. In particular, lack of protein or
phosphorylation alterations in the DH, mPFC, and hypothalamus was unexpected, given
that E2, DPN, and EGX358 all reduced drug-induced vasodilation relative to vehicle and
enhanced memory relative to chance. It was also expected that E2 would alter protein
expression and phosphorylation in the amygdala to reflect the modest anxiolytic effect
treatment had in the open field task. Yet, remarkably, no proteins or phosphorylation
states were altered due to treatment in any of the brain regions examined.
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We investigated several proteins associated with cellular activity and synaptic
plasticity events. c-Fos, an immediate early gene, is often examined as a marker of neural
activity, as stimulation of a cell upregulates c-Fos expression, which functions to promote
subsequent waves of transcription (Gallo et al., 2018; Tyssowski et al., 2018). Upon
cellular stimulation and subsequent phosphorylation, kinases such as ERK and CaMKIIa
phosphorylate hundreds of other protein targets to alter their levels of activity or, in the
case of ERK, translocate into the cellular nucleus to upregulate protein expression, both
processes which are directly implicated in the generation and maintenance of synaptic
plasticity (Adams & Sweatt, 2002; Lisman et al., 2002; Plotnikov et al., 2019; Tyssowski
et al., 2018). The neurotrophin, BDNF, is a well-characterized marker of synaptic
plasticity, functioning to regulate NMDA receptor trafficking and maintenance, as well as
developing and stabilizing dendritic spines, especially as has been shown in regions such
as the hippocampus (Miranda et al., 2019). Synaptophysin and SNAP25 are both proteins
involved in the trafficking of vesicles to the presynaptic membrane, allowing for
neurotransmitter exocytosis (Tomasoni et al., 2013). Upon sufficient postsynaptic
stimulation, PSD95 is recruited to the dendritic spines to anchor factors such as AMPA
and NMDA receptors to the postsynaptic density, sensitizing the postsynaptic cell to
future stimulation (Chen et al., 2011). To facilitate the recruitment of PSD95 and synaptic
strengthening, actin is reorganized to drive changes in dendritic spines. Phosphorylation
of cofilin, for example, allows for the polymerization of actin into filamentous structures
(F-actin), stabilizing the synapse (Basu & Lamprecht, 2018; Gu et al., 2010). Furthermore,
shuttling of GluA2/3-containing AMPA receptors into synapses is thought to gradually
replace GluA1-containing AMPA receptors to stabilize plastic changes and maintain
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connectivity between pre- and postsynaptic sites, which is accomplished by actin
remodeling and stabilization (Basu & Lamprecht, 2018; Diering & Huganir, 2018). All of
these factors work at different phases of plasticity following the activation of cells to
increase the connectivity between pre- and postsynaptic domains. Therefore, these were
candidate proteins to examine in regions implicated in learning, affective, and vasomotor
outcomes following long-term administration of EGX358.
Given the roles E2 plays as a neuromodulator in the hippocampus by inducing
ERK, PKA, and PKC signaling, the trafficking and phosphorylation of AMPA and NMDA
receptors, and remodeling of dendritic spine densities and arbors through the cofilin
pathway, it is surprising not to have captured any similar effects in the DH due to longterm treatment with not only E2, but also DPN or EGX358 (as reviewed in Taxier et al.,
2020). Similar results have been show in the mPFC, where E2 treatment appears to
increase cellular activity and promote dendritic spine densities (Tuscher et al., 2019;
Zeidan et al., 2011). Within the amygdala and hypothalamus, the opposite appears to be
true, such that E2 appears to downregulate activity (Dacks et al., 2011; Zeidan et al.,
2011). Although much less is known about molecular function of ERb in the mPFC,
amygdala, and hypothalamus in relation, it is nonetheless surprising to not have found
any protein or phosphorylation changes in any of these regions either, especially given
the behavioral and physiological results of this study.
Two potential reasons for the seeming lack of biochemical results may be due to
the timing and dosing of the current study. Although the majority of studies examining the
molecular mechanisms underlying E2 and ERb actions in the hippocampus have utilized
short-term or acute administration methods, a handful of long-term studies have
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administered either DPN or utilized ERb-selective phytoestrogen diets. In one study,
feeding OVX mice a phytoestrogen diet with 83-fold selectivity for ERb over ERa at a
dose of roughly 10 mg/kg for 9 months enhanced memory outcomes on the Y-maze and
promoted hippocampal BDNF and PSD95 levels (Zhao et al., 2011). Zhao et al. (2011)
treated their mice for considerably longer than the current study, and at a much higher
dose than that of our DPN or EGX358 groups, which could have promoted responses in
the DH more readily than the current study’s treatments. Another study utilizing highphytoestrogen diets (810 µg/g) for 9 weeks showed increased dendritic spine densities in
the mPFC and DH of OVX rats compared to rats given a low-phytoestrogen diet (Luine
et al., 2006). The timing used by Luine et al. (2006) is remarkably close to the current
study. Importantly, their phytoestrogen dose of 810 µg/g, or 810 mg/kg, is only slightly
higher than that used in our standard diet, which ranges between 350 and 650 mg/kg,
suggesting that diet may in our study may have obfuscated increases in plasticity that
might have otherwise been seen in mice treated with low-phytoestrogen diets. Sárvári
and colleagues (2016) administered DPN via osmotic pump for 29 days at a dose of 0.02
mg/animal/day in 13-month-old OVX rats showed many altered genes in the
hippocampus due to treatment, most notably the increased production of mGluR1,
mGluR5, GluA2, GluA3 mRNA expression, suggestive of increased sensitivity to
glutamatergic signaling in this region. Although the treatment timeline was shorter than
the current study, the use of aged rats and continuous delivery via osmotic pump may
have led to different timing profiles of ERb activation and in a system too dissimilar to the
young mice used in the current study to see similar results. Additionally, 0.02 mg DPN/day
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is roughly 13 times greater than the DPN dose utilized in the current study, which may
also have affected gene and protein expression outcomes differently than here.
Importantly, another factor to consider is the timepoint at which tissues were
collected following the final gavage treatment. Previous studies have shown that
serotonin and metabolites of dopamine and norepinephrine are elevated in the mPFC of
OVX rats 30 min following peripheral E2 injection (Inagaki et al., 2010). Furthermore,
dendritic spine densities in both the mPFC and DH are increased 30 min following E2
injection in OVX rats (Inagaki et al., 2012). On account of these findings, in the current
study, we collected DH, mPFC, amygdala, and hypothalamic tissues 30 minutes following
gavage on the final day of treatment. However, the temporal dynamics of gavage may
differ from that of subcutaneous injection, and to date, there are no studies examining the
time it takes E2 or DPN to reach the brain through gavage. Additionally, we have not
conducted a time course study of EGX358 and therefore do not know how long it takes
the compound to reach brain areas of interest. Therefore, it is possible we simply missed
the timepoints at which E2, DPN, or EGX358 may have affected protein expression and
phosphorylation relative to vehicle treatment.
Another potential explanation for the lack of molecular effects could be the loss of
sensitivity to treatment. For example, given that cellular activity markers like c-Fos are
upregulated in the hippocampus specifically in response to novel contexts or stimulation
types, it is possible that repeated gavage of E2, DPN, or EGX358 was unable to generate
a “novel” enough signal compared to vehicle treatment after 64 days (Bernstein et al.,
2019; Bertaina-Anglade et al., 2000; Mahringer et al., 2019). Specifically, exposure to
novel or semi-novel objects, contexts, or animals is sufficient to drive c-Fos expression in
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the hippocampus, but with re-presentation of each object, context or animal, less c-Fos
is expressed (Bernstein et al., 2019; Bertaina-Anglade et al., 2000; Mahringer et al.,
2019). Therefore, in much the same way, administration of E2, DPN, or EGX358 once per
day may be insufficiently “novel” to the cells of the regions examined, leading to little
cellular activity changes compared to vehicle treatment, and this might expand to the
other proteins examined in this study. Importantly, the lack of treatment effects on protein
expression and phosphorylation cannot simply be attributed loss of ERb, as these
receptors were similar between all groups in both the DH and mPFC. Although we have
previously shown that ERb levels decline in the hippocampus due to time since OVX, it
was found that mice euthanized 2 months following OVX had significantly higher ERb
levels than those euthanized 5 months following OVX (Hanson et al., 2018). Therefore, it
is unlikely that significant decline in ERb would have occurred here, and the current
results demonstrate that treatment did not affect ERb expression.
The effects of stress may also have influenced protein alterations in our regions of
interest. Oral gavage is a stressful method of delivering drugs to rodents, resulting in
elevated plasma and fecal corticosterone levels (Brown et al., 2000; Vandenberg et al.,
2014; Walker et al., 2012). Additionally, repeated behavioral and physiological testing
may have contributed to greater stress levels in the mice in this study. In particular, the
TST and FST are very aversive and are often used not only as measures of depressionlike behaviors, but also as stress-inducing methods (de Kloet & Molendijk, 2016; Krishnan
& Nestler, 2011; Pesarico et al., 2020). The current study was designed to reduce impacts
of stress on behavioral outcomes by conducting less stressful paradigms (e.g., open field)
prior to more stressful paradigms (e.g., forced swim test), and a week separated the FST
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and OP tests to reduce accumulated stress. However, it is possible that, by the end of the
behavioral testing, mice still had moderate to high levels of stress, although this was not
confirmed by corticosterone levels or other markers. Glucocorticoids, such as
corticosterone, have profound effects on cellular responses throughout the brain,
especially in regions laden with glucocorticoid receptors such as the hippocampus. Both
acute and chronic stress can lead to decreases in BDNF expression and phosphorylation
of the transcription factor, CREB, which is also a major target of ERK signaling (as
reviewed in Duman, 2004; Krishnan & Nestler, 2011). Although estrogenic signaling
improves affective outcomes, it is possible that this intersection of signaling affected our
molecular results, given that all regions examined are targets of glucocorticoid signaling.
The lack of novelty of treatment and the stress of repeated gavage and numerous
behaviors likely culminated in the lack of molecular alterations in the DH, mPFC,
amygdala, and hypothalamus. This is further evidenced by the fact that E2 treatment was
only modestly anxiolytic in the open field and that E2, DPN, and EGX358 enhanced
memory outcomes only relative to chance in both the OP and OR tasks, but not relative
to vehicle treatment. However, future studies will be needed to determine whether stress
and sensitivity to treatment did indeed affect these results. Namely, future studies utilizing
an untreated homecage control group and testing acute treatment styles will be highly
informative in parsing the molecular effects of EGX358 treatment.
Effects on Body Weight and Overall Health
Finally, we also show here that long-term treatment with E2 or ERb agonists does not
reduce weight gain following OVX or cause adverse health problems including premature
death. Interestingly, none of our estrogenic treatments prevented weight gain over time
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compared to vehicle. As E2 treatment has previously been shown to reduce OVX-induced
weight gain in both mice and rats, it was surprising that E2-treated mice did not exhibit
significantly lower body weights than vehicle-treated mice (Couse & Korach, 1999;
Torsten Hertrampf et al., 2006; Litwak et al., 2014; Sibonga et al., 1998; Wegorzewska et
al., 2008). This lack of effect may be at least partially mediated by our use of a standard
diet instead of a high-fat diet, as supported by previous rat and mouse studies (Litwak et
al., 2014; Weigt et al., 2012; Yokota-Nakagi et al., 2020). It is not surprising, however, to
find that neither DPN nor EGX358 reduced weight gain compared to vehicle, as previous
studies report mixed results, such that either no effect of phytoestrogen diets or ERb
agonist treatment was observed in rats, positive effects were found only under high-fat
diet conditions in wild-type compared to ERb knockout mice, or negative effects were
shown under standard diet conditions in mice (Foryst-Ludwig et al., 2008; T. Hertrampf
et al., 2007, 2008; Said et al., 2018; Weigt et al., 2012). These findings suggest a stronger
ERa-mediated protective role in body weight regulation.
One potential confound with our body weight measurements is that the
phytoestrogen content (350-650 mg/kg) of our rodent chow might have obscured effects
of long-term estrogen treatments on body mass. Long-term consumption of diets
containing phytoestrogens at roughly the same concentrations as our diet alleviate weight
gain in OVX rats and mice compared to phytoestrogen-free diets (H. K. Kim et al., 2006;
Kishida et al., 2008; Kurrat et al., 2015). However, the only dose to effectively reduce
body mass in Kim et al. (2006) was much higher than our standard chow (1500 mg/kg
versus 350-650 mg/kg, respectively), suggesting that the dose used here may not affect
body mass in mice. It is also possible that the phytoestrogen content in our chow affected
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other measures in this study, as previous work has demonstrated that long-term
consumption of dietary phytoestrogens at similar or lower concentrations than our chow
may confound effects of exogenous E2 on anxiety- and depression-like behaviors and
may have anxiolytic and depression-reducing effects similar to E2 treatment in OVX rats
(Kageyama et al., 2010; Rodríguez-Landa et al., 2017; Russell et al., 2017). However,
that long-term E2 treatment here improved anxiety-like behaviors, and E2, DPN, and
EGX358 improved vasomotor and memory outcomes, suggests that OVX mice require
higher phytoestrogen concentrations than rats to affect these outcomes, which is
supported by Kim et al. (2006). Regardless, a follow-up study examining our
administration doses in OVX mice fed phytoestrogen-free diets may be helpful in
determining whether diet may have confounded results presented here.
That long-term treatment of EGX358 did not increase body weight or result in
premature removal from this study due to health complications or apparent stress
suggests little adverse effects on overall health. These data complement our previous
findings that a single i.p. injection of EGX358 did not affect liver, heart, or kidney tissues
and that EGX358 does not facilitate breast cancer cell proliferation or bind to other nuclear
hormone receptors (Hanson et al., 2018). Collectively, these two studies suggest minimal
negative effects on general health, although more rigorous testing must be conducted in
the future to examine other aspects of overall health (e.g., liver, skeleton, and muscles).
Conclusions
In conclusion, long-term oral treatment of young OVX mice with a novel, highly
selective ERb agonist, EGX358, reduced drug-induced vasodilation and enhanced spatial
and object recognition memory without adverse effects on anxiety- or depression-like
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behaviors, body weight, or overall health. Surprisingly, no treatment effects were seen in
cellular activity markers or synaptic plasticity-related proteins in the DH, mPFC,
amygdala, or hypothalamus, regions highly implicated in learning and memory, affective
outcomes, and hot flash production. Our behavioral and physiological data expand upon
our previous findings in which acute post-training treatment with multiple doses of
EGX358 via hippocampal infusion, i.p. injection, or oral gavage enhanced spatial and
object recognition memory consolidation in young OVX mice (Hanson et al., 2018). Here,
we used the lowest effective oral gavage dose from our previous study (Hanson et al.,
2018) and found that EGX358 not only enhances memory but also mitigates drug-induced
vasodilation, which expands the potential indications for EGX358 drug development to
now include treatment of hot flashes. However, more work is needed to determine the
cellular and molecular effects of EGX358 in the brain.
It should be noted that OVX in young rodents does not perfectly recapitulate the
human menopausal transition. In particular, OVX causes a very abrupt loss of circulating
hormones, including E2, due to the sudden removal of the ovaries, whereas menopause
in humans results in a gradual loss of circulating hormones due to ovarian senescence.
However, the OVX model is useful preclinically to assess effects of exogenous hormones
in the absence of endogenous circulating hormones. Thus, this model is a suitable first
step in determining the potential efficacy of EGX358. Future studies will explore the doseresponse in more detail, and whether higher doses of EGX358 might reduce preclinical
indices of menopause-related anxiety and depression, and test efficacy of EGX358 in
middle-aged females. Although aging female rodents do not undergo complete follicular
loss or experience drops in gonadotrophin levels (Wise, 2000), they do experience
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increases in follicle-stimulating hormone, luteinizing hormone, and E2 prior to a complete
cessation of hormonal cycling (Frick et al., 1999; Lefevre & Mcclintock, 1988; Nelson et
al., 1995), similar to the menopausal transition in human women. Therefore, the
assessment of behavioral and physiological responses to EGX358 in middle-aged female
mice will be a valuable next step in the preclinical development of this compound.
Additionally, future work will be needed to determine the molecular effects of both acute
and long-term treatment of EGX358 in brain regions laden with ERb, such as the DH and
mPFC. Altogether, these results show promise for the development of ERb-driven HTs,
and specifically for EGX358 as a potential therapeutic agent that safely and effectively
reduces menopausal symptoms, thereby enhancing the quality of life for older women.
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